• A First-in-Class Clinical G-Quadruplex-Targeting Drug. The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
    • Xu H, Hurley LH.
    • Bioorg Med Chem Lett. 2022 Oct 1:129016. doi: 10.1016/j.bmcl.2022.129016. Epub ahead of print.
    • Review

    Original research:

    Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov)

    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Oct;65:32-40. doi: 10.1016/j.breast.2022.06.003. Epub 2022 Jun 18.
    • Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.
    • Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, Uliana V, Zanoni D, Tommasi C, Bortesi B, Bonatti F, Piacentini F, Cortesi L, Camisa R, Sgargi P, Michiara M, Musolino A.
    • Breast. 2022 Oct;65:145-150. doi: 10.1016/j.breast.2022.07.012. Epub 2022 Jul 31.
    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25.
    • Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
    • Stodtmann S, Eckert D, Joshi R, Nuthalapati S, Ratajczak CK, Menon R, Mensing S, Xiong H.
    • J Clin Pharmacol. 2022 Oct;62(10):1236-1246. doi: 10.1002/jcph.2061. Epub 2022 May 5.

    Identifier: NCT02163694: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. (ClinicalTrials.gov)

    • Intrathecal Methotrexate Toxicity Resulting in Brain Death due to Generalized Cerebral Edema Case Report.
    • Pang H, Chan JL, Bannykh SI, Gezalian M, Lahiri S, Toossi S, Ayodele M.
    • Neurohospitalist. 2022 Oct;12(4):697-701. doi: 10.1177/19418744221106313. Epub 2022 Jun 6.
    • Case report
    • Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers.
    • Sibilio A, Curcio A, Toesca A, Rossi EMC, Corso G.
    • Curr Opin Oncol. 2022 Sep 28. doi: 10.1097/CCO.0000000000000872. Epub ahead of print.
    • Review
    • Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    • Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O.
    • J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595.
    • BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
    • Pavese F, Capoluongo ED, Muratore M, Minucci A, Concetta Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, D’Angelo T, Franceschini G, Masetti R, Fabi A, Mulè A, Santoro A, Belli P, Tortora G, Scambia G, Paris I.
    • Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14184571.
    • TSG101 associates with PARP1 and is essential for PARylation and DNA damage-induced NF-?B activation.
    • Tufan AB, Lazarow K, Kolesnichenko M, Sporbert A, von Kries JP, Scheidereit C.
    • EMBO J. 2022 Sep 20:e110372. doi: 10.15252/embj.2021110372. Epub ahead of print.
    • Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
    • Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A.
    • J Clin Oncol. 2022 Sep 20;40(27):3205-3221. doi: 10.1200/JCO.22.01063. Epub 2022 Jun 27.
    • Patient-Associated Risk Factors for Severe Anemia in Patients with Advanced Ovarian or Breast Cancer Receiving Olaparib Monotherapy: A Multicenter Retrospective Study.
    • Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T.
    • Front Oncol. 2022 Sep 16;12:898150. doi: 10.3389/fonc.2022.898150.
    • Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: a case report.
    • Gomez-Puerto D, Llop-Guevara A, Cruellas M, Torres-Esquius S, De La Torre J, Peg V, Balmaña J, Pimentel I.
    • Front Oncol. 2022 Sep 14;12:963728. doi: 10.3389/fonc.2022.963728.
    • Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Pinto L, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2022 Sep 9;20(1):34. doi: 10.1186/s13053-022-00242-0.
    • From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
    • De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Franceschini R, Tancredi R, Pedrazzoli P, Santoro A, Zambelli A.
    • Front Pharmacol. 2022 Sep 8;13:909566. doi: 10.3389/fphar.2022.909566.
    • Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.
    • Park SY, Suh KJ, Lee DW, Ryu HS, Kim M, Kim SH, Lee KH, Kim TY, Kim JH, Park IA, Im SA.
    • Breast Cancer Res Treat. 2022 Sep 7. doi: 10.1007/s10549-022-06566-8. Epub ahead of print.
    • Genomics to select treatment for patients with metastatic breast cancer.
    • Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I.
    • Nature. 2022 Sep 7. doi: 10.1038/s41586-022-05068-3. Epub ahead of print.

    Identifier: NCT02299999: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast). (ClinicalTrials.gov)

    Identifier: NCT03386162: SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer (SAFIR-PI3K). (ClinicalTrials.gov)

    • Next-generation sequencing based detection of BRCA1 and BRCA2 large genomic rearrangements in Chinese cancer patients.
    • Hua D, Tian Q, Wang X, Bei T, Cui L, Zhang B, Bao C, Bai Y, Zhao X, Yuan P.
    • Front Oncol. 2022 Sep 6;12:898916. doi: 10.3389/fonc.2022.898916.
    • STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer.
    • Pantelidou C, Jadhav H, Kothari A, Liu R, Wulf GM, Guerriero JL, Shapiro GI.
    • NPJ Breast Cancer. 2022 Sep 6;8(1):102. doi: 10.1038/s41523-022-00471-5.
    • UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer.
    • [No author given]
    • Precision Oncology News. Business, Policy & Funding. 2022 Sep 6.
    • PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
    • Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F.
    • Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
    • A progressive and refractory case of breast cancer with Cowden syndrome.
    • Sueta A, Takeno M, Goto-Yamaguchi L, Tomiguchi M, Inao T, Yamamoto-Ibusuki M, Yamamoto Y.
    • World J Surg Oncol. 2022 Sep 3;20(1):279. doi: 10.1186/s12957-022-02745-5.
    • A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
    • Jia X, Wang K, Xu L, Li N, Zhao Z, Li M.
    • Breast. 2022 Sep 2;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub ahead of print.
    • Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    • Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM.
    • Clin Cancer Res. 2022 Sep 1:CCR-22-0749. doi: 10.1158/1078-0432.CCR-22-0749. Epub ahead of print.

    Identifier: NCT01623349: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer. (ClinicalTrials.gov)

    Identifier: NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC). (ClinicalTrials.gov)

    • Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278.
    • BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    • Blatnik A, Ribnikar D, Šetrajcic Dragoš V, Novakovic S, Stegel V, Grcar Kuzmanov B, Boc N, Peric B, Škerl P, Klancar G, Krajc M.
    • Breast Cancer. 2022 Sep;29(5):921-927. doi: 10.1007/s12282-022-01354-0. Epub 2022 Apr 5.
    • Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.
    • Saule C, Menu-Hespel S, Carton M, Malhaire C, Cherel P, Reyal F, Le Mentec M, Guillot E, Donnadieu A, Callet N, Frank S, Coussy F, Stoppa-Lyonnet D, Mouret-Fourme E.
    • Eur J Hum Genet. 2022 Sep;30(9):1060-1066. doi: 10.1038/s41431-022-01049-2. Epub 2022 Feb 25.
    • Breast cancer in a teenage girl with BRCA mutation: A case report from a low middle-income country.
    • Vohra LM, Ali D, Hashmi SA, Angez M.
    • Int J Surg Case Rep. 2022 Sep;98:107513. doi: 10.1016/j.ijscr.2022.107513. Epub 2022 Aug 13.
    • PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.
    • Pauwels EKJ, Bourguignon MH.
    • Med Princ Pract. 2022 [Sep];31(4):303-312. doi: 10.1159/000525281. Epub 2022 May 30.
    • Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
    • Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T.
    • Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355.
    • Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
    • Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah V.
    • ESMO Open. 2022 Aug 26;7(5):100571. doi: 10.1016/j.esmoop.2022.100571. Epub ahead of print.

    Identifier: NCT02454972: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors. (ClinicalTrials.gov)

    • Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Aug 26.
    • PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.
    • Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J, Chen H, Zhao X, Yang L, Lu H.
    • Front Pharmacol. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633.
    • Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
    • Garufi G, Carbognin L, Schettini F, Seguí E, Di Leone A, Franco A, Paris I, Scambia G, Tortora G, Fabi A.
    • Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
    • A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    • Zeng T, Sun C, Liang Y, Yang F, Yan X, Bao S, Zhang Y, Huang X, Fu Z, Li W, Yin Y.
    • Cancers (Basel). 2022 Aug 23;14(17):4084. doi: 10.3390/cancers14174084.
    • Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
    • Leung JH, Tai YS, Wang SY, Tsung-Chin H, Yip FH, Chan AL, Yu-Chen H.
    • Expert Opin Drug Saf. 2022 Aug 23. doi: 10.1080/14740338.2022.2116001. Epub ahead of print.
    • Meta-Analysis
    • PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
    • Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV.
    • Mol Cancer Ther. 2022 Aug 23:MCT-22-0217. doi: 10.1158/1535-7163.MCT-22-0217. Epub ahead of print.
    • Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    • Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C, Curigliano G, Tolaney SM, Barroso-Sousa R.
    • Cancer Treat Rev. 2022 Aug 18;110:102459. doi: 10.1016/j.ctrv.2022.102459. Epub ahead of print.
    • Review
    • Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
    • Lucas MW, Kelly CM.
    • Cancer Manag Res. 2022 Aug 17;14:2493-2506. doi: 10.2147/CMAR.S341466.
    • Triple negative breast cancer: approved treatment options and their mechanisms of action.
    • Mandapati A, Lukong KE.
    • J Cancer Res Clin Oncol. 2022 Aug 17. doi: 10.1007/s00432-022-04189-6. Epub ahead of print.
    • Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study.
    • Wang N, Yu X.
    • Front Immunol. 2022 Aug 15;13:901636. doi: 10.3389/fimmu.2022.901636.
    • Targeted therapy for breast cancer: An overview of drug classes and outcomes.
    • Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L.
    • Biochem Pharmacol. 2022 Aug 13:115209. doi: 10.1016/j.bcp.2022.115209. Epub ahead of print.
    • Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Aug 4.
    • Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients.
    • Fasching PA, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, Ekici AB, Reis A, Schneeweiss A, Tesch H, Fehm TN, Heinrich G, Beckmann MW, Ruebner M, Huebner H, Lambrechts D, Madden E, Shen J, Romm J, Doheny K, Jenkins GD, Carlson EE, Li L, Fridley BL, Cunningham JM, Janni W, Monteiro ANA, Schaid DJ, Häberle L, Weinshilboum RM, Wang L.
    • Clin Cancer Res. 2022 Aug 2;28(15):3342-3355. doi: 10.1158/1078-0432.CCR-20-4774.
    • Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    • Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard FC, Richard F, Yang WW, Steele RE, Pettitt SJ, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-Salomon A, Derksen PWB, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C.
    • Ann Oncol. 2022 Aug;33(8):769-785. doi: 10.1016/j.annonc.2022.05.006. Epub 2022 May 21.
    • A commentary on the discrepancy between blood and tumour BRCA testing: An open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Aug;129(9):1422-1426. doi: 10.1111/1471-0528.17158. Epub 2022 Apr 5.

    Commentary:

    Gene sequencing in ovarian cancer: continually moving targets.

    • The landscape of systemic therapy for early stage triple negative breast cancer.
    • Lu JY, Alvarez Soto A, Anampa JD.
    • Expert Opin Pharmacother. 2022 Aug;23(11):1291-1303. doi: 10.1080/14656566.2022.2095902. Epub 2022 Jul 25.
    • Review
    • Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
    • Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ.
    • Nat Cancer. 2022 Aug;3(8):927-931. doi: 10.1038/s43018-022-00400-2. Epub 2022 Jul 4. Erratum in: Nat Cancer. 2022 Aug 5.

    Identifier: NCT03329937: Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer. (ClinicalTrials.gov)

    • The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point.
    • Kalinowski L, Viale G, Domchek S, Tutt A, Lucas PC, Lakhani SR.
    • Pathology. 2022 Aug;54(5):511-516. doi: 10.1016/j.pathol.2022.05.003. Epub 2022 Jun 29.
    • Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    • Kotani H, Masuda N, Yamashita T, Naito Y, Taira T, Inoue K, Takahashi M, Yonemori K, Toyoizumi S, Mori Y, Nagasawa T, Hori N, Iwata H.
    • Breast Cancer. 2022 Jul 30. doi: 10.1007/s12282-022-01390-w. Epub ahead of print.

    Identifier: NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors. (ClinicalTrials.gov)

    • PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
    • Kim D, Nam HJ.
    • Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • High grade acinic cell carcinoma of the breast with clear cytoplasm mimics clear cell carcinoma in a BRCA1 mutation carrier: a case report and review of the literature on the molecular analysis.
    • Min L, Qiao H, Hongkai Z.
    • Histol Histopathol. 2022 Jul 27:18501. doi: 10.14670/HH-18-501. Epub ahead of print.
    • Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants.
    • Edaily S, Abdel-Razeq H.
    • Onco Targets Ther. 2022 Jul 27;15:815-826. doi: 10.2147/OTT.S369844.
    • Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    • de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
    • J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer.
    • Pauls M, Chia S, LeVasseur N.
    • Curr Oncol. 2022 Jul 7;29(7):4748-4767. doi: 10.3390/curroncol29070377.
    • Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
    • MacDonald I, Nixon NA, Khan OF.
    • Curr Oncol. 2022 Jul 7;29(7):4768-4778. doi: 10.3390/curroncol29070378.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.
    • Yoshimura A, Imoto I, Iwata H.
    • Int J Mol Sci. 2022 Jul 5;23(13):7481. doi: 10.3390/ijms23137481.
    • New Adjuvant Treatment for High-Risk Early Breast Cancer.
    • Aschenbrenner DS.
    • Am J Nurs. 2022 Jul 1;122(7):26. doi: 10.1097/01.NAJ.0000842240.11650.1d.
    • News
    • Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.
    • Kurian AW, Abrahamse P, Hamilton AS, Caswell-Jin JL, Gomez SL, Hofer TJ, Ward KC, Katz SJ.
    • JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac045. doi: 10.1093/jncics/pkac045.
    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.
    • van Barele M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, Koppert LB, Loo CE, Tollenaar RAEM, Ausems MGEM, van de Beek I, Berger LPV, de Boer M, van Hest LP, Kets CM, Rookus M; Hebon, Schmidt MK, Jager A, Hooning MJ.
    • Breast Cancer Res Treat. 2022 Jul;194(1):159-170. doi: 10.1007/s10549-022-06608-1. Epub 2022 May 4.
    • Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    • Wang X, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P.
    • Curr Cancer Drug Targets. 2022 [Jul];22(6):530-536. doi: 10.2174/1568009622666220214092207.
    • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    • McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B.
    • Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.
    • Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data.
    • Suh KJ, Kim SH, Kim YJ, Shin H, Kang E, Kim EK, Lee S, Woo JW, Na HY, Ahn S, Jang BS, Kim IA, Park SY, Kim JH.
    • J Breast Cancer. 2022 Jun 28. doi: 10.4048/jbc.2022.25.e30. Epub ahead of print.
    • Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation.
    • Zarbiv Y, Wygoda YB, Grinshpun A, Hamburger T, Sella T, Breuer S, Maimon O, Rottenberg Y, Peretz T, Kadouri L.
    • Oncol Ther. 2022 Jun 25. doi: 10.1007/s40487-022-00202-7. Epub ahead of print.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Jun 18. doi: 10.1245/s10434-022-12048-4. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    • Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J.
    • Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y.
    • Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    • Mekonnen N, Yang H, Shin YK.
    • Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors.
    • Piombino C, Cortesi L.
    • Cancers (Basel). 2022 Jun 5;14(11):2804. doi: 10.3390/cancers14112804.
    • Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.
    • Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Thomssen C, Witzel I, Fehm TN, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf AD, Wöckel A, Seliger B, Massa C, Kolberg HC.
    • Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):580-589. doi: 10.1055/a-1811-6106.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Jun 1;28(11):2201-2203. doi: 10.1158/1078-0432.CCR-22-0442.
    • Commentary

    Original research:

    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • ASO Author Reflections: Broaden the Targeted Population of Synthetic Lethality for Taiwanese Breast Cancer.
    • Huang CC, Tseng LM.
    • Ann Surg Oncol. 2022 Jun;29(6):3591-3592. doi: 10.1245/s10434-022-11407-5. Epub 2022 Apr 7.
    • Commentary
    • The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    • Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D'Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB.
    • Ann Surg Oncol. 2022 Jun;29(6):3810-3819. doi: 10.1245/s10434-022-11367-w. Epub 2022 Mar 5.
    • Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities.
    • Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001. Epub 2022 May 9.
    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    • de Boo LW, Józwiak K, Joensuu H, Lindman H, Lauttia S, Opdam M, van Steenis C, Brugman W, Kluin RJC, Schouten PC, Kok M, Nederlof PM, Hauptmann M, Linn SC.
    • Br J Cancer. 2022 Jun;126(10):1401-1409. doi: 10.1038/s41416-022-01711-y. Epub 2022 Feb 5.
    • Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    • Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC.
    • Clin Breast Cancer. 2022 Jun;22(4):319-325. doi: 10.1016/j.clbc.2021.12.007. Epub 2021 Dec 30.
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Jun;31(6):607-631. doi: 10.1080/13543784.2022.2067527. Epub 2022 May 3.
    • Review
    • Q and A: A New Standard of Care for Germline BRCA1 and/or BRCA2 Mutation Carriers With Early-Stage Breast Cancer.
    • Desai NV, Zakalik D, Somerfield MR, Tung NM.
    • JCO Oncol Pract. 2022 Jun;18(6):427-429. doi: 10.1200/OP.21.00770. Epub 2022 Jan 7.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?
    • Boulos M, Moujaes E, Nsouli G, Tfayli A, Kourie HR.
    • Pharmacogenomics. 2022 Jun;23(8):487-492. doi: 10.2217/pgs-2022-0011. Epub 2022 May 24.
    • Review
    • Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results.
    • Ong SS, Ho PJ, Khng AJ, Lim EH, Wong FY, Tan BK, Lim SH, Tan EY, Tan SM, Tan VKM, Dent R, Tan TJY, Ngeow J, Madhukumar P, Hamzah JLB, Sim Y, Lim GH, Pang JS, Alcantara VS, Chan PMY, Chen JJC, Kuah S, Seah JCM, Buhari SA, Tang SW, Ng CWQ, Li J, Hartman M.
    • Cancers (Basel). 2022 May 31;14(11):2714. doi: 10.3390/cancers14112714.
    • STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
    • Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ.
    • Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1.
    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.
    • OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
    • Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
    • Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.
    • Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
    • Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT.
    • NPJ Breast Cancer. 2022 May 10;8(1):64. doi: 10.1038/s41523-022-00427-9.
    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.
    • Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
    • Pai Bellare G, Sankar Patro B.
    • Biochem Pharmacol. 2022 May;199:115024. doi: 10.1016/j.bcp.2022.115024. Epub 2022 Mar 31.
    • A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    • Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team.
    • Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18.
    • Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
    • BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1.
    • BRCA2-associated Breast Cancer in Transgender Women: Reconstructive Challenges and Literature Review.
    • Cole NA, Copeland-Halperin LR, Shank N, Shankaran V.
    • Plast Reconstr Surg Glob Open. 2022 Apr 22;10(4):e4059. doi: 10.1097/GOX.0000000000004059.
    • Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients.
    • Hu L, Sun J, Li Z, Qu Z, Liu Y, Wan Q, Liu J, Ding X, Zang F, Zhang J, Yao L, Xu Y, Wang Y, Xie Y.
    • NPJ Breast Cancer. 2022 Apr 21;8(1):52. doi: 10.1038/s41523-022-00417-x.
    • Choroidal Metastasis With Secondary Retinal Detachment in a Man With BCRA2-Associated Breast Adenocarcinoma.
    • Sanayei N, Davoudi S, Port A, Chen X.
    • Cureus. 2022 Apr 18;14(4):e24243. doi: 10.7759/cureus.24243.
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    • Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL.
    • Clin Cancer Res. 2022 Apr 14;28(8):1493-1499. doi: 10.1158/1078-0432.CCR-21-3045.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • PARP inhibition in breast cancer: progress made and future hopes.
    • Tung N, Garber JE.
    • NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
    • Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    • Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.
    • Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.
    • Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
    • Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
    • Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmaña J.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350232.
    • Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    • Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH.
    • Breast. 2022 Apr;62:52-60. doi: 10.1016/j.breast.2022.01.014. Epub 2022 Jan 29.
    • Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
    • Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V.
    • ESMO Open. 2022 Apr;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub 2022 Feb 26. Erratum in: ESMO Open. 2022 Apr 7;7(3):100472.
    • First international workshop of the ATM and cancer risk group (4-5 December 2019).
    • Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L; Spanish ATM working group, Arun B, Herold N, Versmold B, Schmutzler RK; GC-HBOC, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE; CARRIERS and Ambry Groups, Stoppa-Lyonnet D, Andrieu N.
    • Fam Cancer. 2022 Apr;21(2):211-227. doi: 10.1007/s10689-021-00248-y. Epub 2021 Jun 14.
    • Conference report
    • Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    • Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E.
    • NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1.
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.
    • Valente PMS, Gomes MCB, Martins WA, Castilho SR.
    • J Oncol Pharm Pract. 2022 Mar 23:10781552221080081. doi: 10.1177/10781552221080081. Epub ahead of print.
    • Case report
    • Olaparib in gBRCA+ Breast Cancer; 'Clearly Practice Changing'.
    • Worcester S.
    • Medscape Oncology. 2022 Mar 18.
    • Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing.
    • Hopkins C.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Mar 17.
    • News

    Clinical Trials: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). (ClinicalTrials.gov)

    Guideline: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) — Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. (National Comprehensive Cancer Network)

    • U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
    • Arora S, Narayan P, Osgood CL, Wedam S, Prowell TM, Gao JJ, Shah M, Krol D, Wahby S, Royce M, Ghosh S, Philip R, Ison G, Berman T, Brus C, Bloomquist EW, Fiero MH, Tang S, Pazdur R, Ibrahim A, Amiri-Kordestani L, Beaver JA.
    • Clin Cancer Res. 2022 Mar 15;28(6):1072-1086. doi: 10.1158/1078-0432.CCR-21-2600.
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer.
    • Worcester S.
    • Medscape. Oncology. 2022 Mar 14.

    Press Release: FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy. (Merck)

    Press Release: Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer. (Myriad Genetics)

    • Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer with or without or with Unknown BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and Four EU Countries.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Breast Care (Basel). 2022 Mar 11. doi: 10.1159/000523970. Epub ahead of print.
    • FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Regulatory News. 2022 Mar 11.
    • PARP Inhibitors Resistance: Mechanisms and Perspectives.
    • Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D.
    • Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420.
    • Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
    • Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0.
    • BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.
    • Fu X, Tan W, Song Q, Pei H, Li J.
    • Front Cell Dev Biol. 2022 Mar 1;10:813457. doi: 10.3389/fcell.2022.813457.
    • Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    • Han HS, Arun BK, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bach BA, Kundu MG, Khandelwal N, Feng D, Bhattacharya S, Maag D, Ratajczak CK, Diéras V.
    • Ann Oncol. 2022 Mar;33(3):299-309. doi: 10.1016/j.annonc.2021.11.018. Epub 2021 Nov 30.
    • Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    • Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y.
    • Breast Cancer. 2022 Mar;29(2):368-376. doi: 10.1007/s12282-021-01319-9. Epub 2022 Jan 5.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    • Guney Eskiler G, Ozturk M.
    • Cell Signal. 2022 Mar;91:110229. doi: 10.1016/j.cellsig.2021.110229. Epub 2021 Dec 24.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • A review on mechanisms of resistance to PARP inhibitors.
    • Desai C, Pathak A, Limaye S, Maniar V, Joshi A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S119-S129. doi: 10.4103/ijc.IJC_53_21.
    • Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
    • Vaid AK, Deshmukh C, Rohatgi N, Ghosh J.
    • Indian J Cancer. 2022 Mar;59(Supplement):S130-S141. doi: 10.4103/ijc.IJC_30_21.
    • Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
    • Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V.
    • JCO Precis Oncol. 2022 Mar;6:e2100140. doi: 10.1200/PO.21.00140.
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
    • Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
    • Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.
    • Review
    • Post-Neoadjuvant Treatment Strategies in Breast Cancer.
    • Matuschek C, Jazmati D, Bölke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckhäberle E, Fehm T, Nestle Krämling C, Dommach M, Haussmann J.
    • Cancers (Basel). 2022 Feb 28;14(5):1246. doi: 10.3390/cancers14051246.
    • Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
    • Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z.
    • Cancers (Basel). 2022 Feb 28;14(5):1253. doi: 10.3390/cancers14051253.
    • Quality of life for people with early-stage breast cancer.
    • [No author given]
    • FORCE. XRAY. 2022 Feb 22.
    • Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    • Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
    • J Pers Med. 2022 Feb 21;12(2):323. doi: 10.3390/jpm12020323.
    • BRCA1/2 Mutations and Cardiovascular Function in Breast Cancer Survivors.
    • Demissei BG, Lv W, Wilcox NS, Sheline K, Smith AM, Sturgeon KM, McDermott-Roe C, Musunuru K, Lefebvre B, Domchek SM, Shah P, Ky B.
    • Front Cardiovasc Med. 2022 Feb 15;9:833171. doi: 10.3389/fcvm.2022.833171.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
    • Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI.
    • JCO Precis Oncol. [2022 Feb 9];6:e2100456. doi: 10.1200/PO.21.00456.
    • Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    • Landry I, Sumbly V, Vest M.
    • Cureus. 2022 Feb 7;14(2):e21970. doi: 10.7759/cureus.21970.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.
    • Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.
    • Imyanitov EN, Iyevleva AG.
    • Cancer Lett. 2022 Feb 1;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.
    • Review
    • Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.
    • Ntemou E, Vidal PD, Alexandri C, Van den Steen G, Lambertini M, Demeestere I.
    • Sci Rep. 2022 Feb 1;12(1):1658. doi: 10.1038/s41598-022-05357-x.
    • Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
    • Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M; HEBON Investigators, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
    • Breast. 2022 Feb;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.
    • Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
    • Lux MP, Decker T, Runkel ED, Niyazov A, Quek RGW, Marschner N, Harbeck N.
    • Breast Care (Basel). 2022 Feb;17(1):40-46. doi: 10.1159/000513596. Epub 2021 Feb 18.
    • Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.
    • Thomssen C, Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Belleville E, Bader S, Untch M, Welslau M, Thill M, Hartkopf AD, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R.
    • Geburtshilfe Frauenheilkd. 2022 Feb 11 [eCollection 2022 Feb];82(2):206-214. doi: 10.1055/a-1724-9639.
    • Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
    • Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A.
    • Int J Mol Sci. 2022 Jan 31;23(3):1665. doi: 10.3390/ijms23031665.
    • Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
    • Cosgrove N, Varešlija D, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ, Young LS.
    • Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.
    • PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
    • Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B.
    • Cancers (Basel). 2022 Jan 25;14(3):599. doi: 10.3390/cancers14030599.
    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • Real-world evidence of the management and prognosis of young women (<40 years) with de novo metastatic breast cancer.
    • Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, De La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Sébastien Frenel J.
    • Ther Adv Med Oncol. 2022 Jan 21;14:17588359211070362. doi: 10.1177/17588359211070362.
    • Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    • Schwartz CJ, da Silva EM, Marra A, Gazzo AM, Selenica P, Rai VK, Mandelker D, Pareja F, Misyura M, D'Alfonso TM, Brogi E, Drullinsky P, Razavi P, Robson ME, Drago JZ, Wen HY, Zhang L, Weigelt B, Shia J, Reis-Filho JS, Zhang H.
    • Clin Cancer Res. 2022 Jan 15;28(2):404-413. doi: 10.1158/1078-0432.CCR-21-2027. Epub 2021 Oct 19.
    • Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2022 Jan 14.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.
    • Sankaranarayanan RA, Peil J, Vogg ATJ, Bolm C, Terhorst S, Classen A, Bauwens M, Maurer J, Mottaghy F, Morgenroth A.
    • Cancers (Basel). 2022 Jan 4;14(1):230. doi: 10.3390/cancers14010230.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Platinum-based systematic therapy in triple-negative breast cancer.
    • Zhu Y, Hu Y, Tang C, Guan X, Zhang W.
    • Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678. doi: 10.1016/j.bbcan.2022.188678. Epub 2022 Jan 10.
    • Review
    • Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    • Suzuki Y, Wenwen W, Ohta T, Hayashi SI.
    • Breast Cancer. 2022 Jan;29(1):77-91. doi: 10.1007/s12282-021-01282-5. Epub 2021 Aug 3.
    • Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    • Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, Wang X, Yue J, Wang J, Yang Z, Cai R, Ma F, Fan Y, Li Q, Zhang P, Xu B, Yuan P.
    • Breast Cancer Res Treat. 2022 Jan;191(1):97-105. doi: 10.1007/s10549-021-06401-6. Epub 2021 Oct 14.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    • Vidra R, Nemes A, Vidrean A, Pintea S, Tintari S, Deac A, Ciuleanu T.
    • Exp Ther Med. 2022 Jan;23(1):91. doi: 10.3892/etm.2021.11014. Epub 2021 Nov 26.
    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
    • Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V.
    • Ther Adv Med Oncol. 2021 Dec 9;13:17588359211059601. doi: 10.1177/17588359211059601.
    • Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
    • Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X.
    • Front Pharmacol. 2021 Dec 6;12:770663. doi: 10.3389/fphar.2021.770663.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.
    • A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    • Pavone G, Motta L, Martorana F, Motta G, Vigneri P.
    • Molecules. 2021 Dec 1;26(23):7294. doi: 10.3390/molecules26237294.
    • PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    • Fuentes-Antrás J, Cescon DW.
    • Ann Oncol. 2021 Dec;32(12):1460-1462. doi: 10.1016/j.annonc.2021.10.005. Epub 2021 Oct 19.
    • Commentary
    • Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V.
    • Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
    • Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
    • Sun X, Wang X, Zhang J, Zhao Z, Feng X, Liu L, Ma Z.
    • Breast. 2021 Dec;60:26-34. doi: 10.1016/j.breast.2021.08.009. Epub 2021 Aug 21.
    • Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    • Sakach E, O'Regan R, Meisel J, Li X.
    • Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17.
    • Review
    • Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    • Patsouris A, Diop K, Tredan O, Nenciu D, Gonçalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Droin N, Bièche I, Callens C, Loehr A, Vicier C, Guerin C, Filleron T, André F.
    • Eur J Cancer. 2021 Dec;159:283-295. doi: 10.1016/j.ejca.2021.09.028. Epub 2021 Nov 25.
    • [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
    • Nakagawa T, Oda G, Okamoto K, Ishikawa T, Wakana K, Oshima N.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1556-1558. Japanese.
    • Case report. [Article in Japanese]
    • [A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy].
    • Suzuki T, Hashimoto N, Yokoyama K, Yoshida T, Yamauchi Y, Sawano T, Ohashi M, Kimura A, Kato M, Umehara Y, Murata A, Takahash K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1840-1842. Japanese.
    • Case report. [Article in Japanese]
    • Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
    • Naito Y, Kuboki Y, Ikeda M, Harano K, Matsubara N, Toyoizumi S, Mori Y, Hori N, Nagasawa T, Kogawa T.
    • Invest New Drugs. 2021 Dec;39(6):1568-1576. doi: 10.1007/s10637-021-01120-7. Epub 2021 Jun 23.

    Identifier: NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors. (ClinicalTrials.gov)

    • Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for BRCA-mutated breast cancer: A systematic review and meta-analysis.
    • Zhang M, Yu X, Wang J, Li Y, Cao L.
    • J Cancer Res Ther. 2021 Dec;17(7):1672-1678. doi: 10.4103/jcrt.jcrt_2085_21.
    • CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.
    • Saleh L, Wilson C, Holen I.
    • MedComm (2020). 2021 Nov 17;2(4):514-530. doi: 10.1002/mco2.97. eCollection 2021 Dec.
    • Influence of germline BRCA genotype on the survival of patients with triple-negative breast cancer.
    • Villarreal-Garza C, Ferrigno AS, Aranda-Gutierrez A, Frankel PH, Ruel NH, Fonseca A, Narod S, Chavarri-Guerra Y, Sifuentes E, Magallanes-Hoyos MC, Herzog J, Castillo D, Alvarez-Gomez RM, Mohar-Betancourt A, Weitzel JN.
    • Cancer Res Commun. 2021 Dec;1(3):140-147. doi: 10.1158/2767-9764.crc-21-0099. Epub 2021 Dec 8.
    • Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
    • Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Carrillo Albornoz PB, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.
    • Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16.

    Research news: Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows. (Precision Oncology News; subscription required)

    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 30.
    • Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
    • Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F.
    • Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280.
    • A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2.
    • Kitahara M, Hozumi Y, Machinaga M, Hayashi Y.
    • Case Rep Oncol. 2021 Nov 18;14(3):1645-1651. doi: 10.1159/000520148.
    • Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study.
    • Elsamany S, Elbaiomy M, Zeeneldin A, Tashkandi E, Hassanin F, Abdelhafeez N, O Al-Shamsi H, Bukhari N, Elemam O.
    • JMIR Cancer. 2021 Nov 15;7(4):e27073. doi: 10.2196/27073.
    • Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
    • Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG.
    • NPJ Breast Cancer. 2021 Nov 11;7(1):142. doi: 10.1038/s41523-021-00349-y.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
    • Harvey-Jones E, Vinas Villaro G, Tutt A.
    • Cancer J. 2021 Nov-Dec 01;27(6):441-456. doi: 10.1097/PPO.0000000000000559.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    • Pham MM, Hinchcliff E, Avila M, Westin SN.
    • Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
    • Miller RE.
    • Cancer J. 2021 Nov-Dec 01;27(6):506-510. doi: 10.1097/PPO.0000000000000565.
    • Review
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
    • Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.
    • Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871.
    • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    • Li Y, Zhan Z, Yin X, Fu S, Deng X.
    • Front Oncol. 2021 Oct 28;11:731535. doi: 10.3389/fonc.2021.731535.
    • Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    • Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, Zheng H.
    • Front Oncol. 2021 Oct 28;11:742139. doi: 10.3389/fonc.2021.742139.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    • Mehta P, Bothra SJ.
    • Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23.
    • Review. Book chapter
    • Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance.
    • Singh DD, Parveen A, Yadav DK.
    • Biomedicines. 2021 Oct 21;9(11):1512. doi: 10.3390/biomedicines9111512.
    • Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
    • Kim JY, Oh JM, Park YH, Ahn JS, Im YH.
    • Front Oncol. 2021 Oct 21;11:759150. doi: 10.3389/fonc.2021.759150.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
    • Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A.
    • Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198.
    • The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    • Greer AC, Lanes A, Poorvu PD, Kennedy P, Thomas AM, Partridge AH, Ginsburg ES.
    • Cancer. 2021 Oct 15;127(20):3872-3880. doi: 10.1002/cncr.33601. Epub 2021 Jun 23.
    • PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.
    • Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW.
    • J Pers Med. 2021 Oct 8;11(10):1009. doi: 10.3390/jpm11101009.
    • Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    • Nozawa K, Yoshimura A, Iwata H.
    • N Engl J Med. 2021 Oct 7;385(15):1439. doi: 10.1056/NEJMc2112373.
    • Letter, Comment

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    • Hoshi A, Bando H, Sekine I.
    • N Engl J Med. 2021 Oct 7;385(15):1439-1440. doi: 10.1056/NEJMc2112373.
    • Letter, Comment

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India.
    • Bajpai J, Ventrapati P, Joshi S, Wadasadawala T, Rath S, Pathak R, Nandhana R, Mohanty S, Chougle Q, Engineer M, Abraham N, Ghosh J, Nair N, Gulia S, Popat P, A P, Sheth T, Desai S, Thakur M, Rangrajan V, Parmar V, Sarin R, Gupta S, Badwe RA.
    • Breast. 2021 Oct 6;60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub ahead of print.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
    • Chang XF, Ren XL, Yang JQ, Shi JJ, Bai JH, Cui MS, Dong WW.
    • Breast. 2021 Oct;59:44-50. doi: 10.1016/j.breast.2021.05.009. Epub 2021 May 27.
    • Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    • Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB.
    • Cancer Res Treat. 2021 Oct;53(4):1084-1095. doi: 10.4143/crt.2020.1381. Epub 2021 Mar 24.
    • Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    • Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M; Breast Cancer Therapy Expert Group (BCTEG).
    • Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.
    • Review
    • BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis.
    • Pan JN, Lei L, Ye WW, Wang XJ, Cao WM.
    • J Breast Cancer. 2021 Oct;24(5):474-480. doi: 10.4048/jbc.2021.24.e39. Epub 2021 Sep 7.
    • Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.
    • Hayward SB, Ciccia A.
    • Curr Opin Genet Dev. 2021 Sep 25;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub ahead of print.
    • Review
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    • Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, Andújar-Sánchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J.
    • Mol Cell. 2021 Sep 18:S1097-2765(21)00739-5. doi: 10.1016/j.molcel.2021.09.005. Epub ahead of print.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
    • Bruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, Rüland A, Kostara A, Chiari O, Dittmer-Grabowski C, Reinisch M.
    • Cancers (Basel). 2021 Sep 11;13(18):4564. doi: 10.3390/cancers13184564.
    • Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
    • Tung NM, Zakalik D, Somerfield MR; Hereditary Breast Cancer Guideline Expert Panel.
    • J Clin Oncol. 2021 Sep 10;39(26):2959-2961. doi: 10.1200/JCO.21.01532. Epub 2021 Aug 3.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    • Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.
    • Ann Oncol. 2021 Sep 6:S0923-7534(21)04458-6. doi: 10.1016/j.annonc.2021.08.2154. Epub ahead of print.
    • Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
    • Altundag K.
    • J BUON. 2021 Sep-Oct;26(5):2202.

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • [A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].
    • Soyama M, Kunihisa T, Shimada N, Suzuki H, Ookawa Y, Okamoto A, Yamamoto M, Miki M, Mizumoto S, Baba M, Tanino H.
    • Gan To Kagaku Ryoho. 2021 Sep;48(9):1153-1155. Japanese.
    • Case report. [Article in Japanese]
    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
    • Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH, de Gramont A, Koeffler HP.
    • Oncotarget. 2021 Aug 31;12(18):1749-1762. doi: 10.18632/oncotarget.28047.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer.
    • Carbonara N, La Forgia D, Pellegrino R, Ressa C, Tommasi S.
    • J Pers Med. 2021 Aug 27;11(9):847. doi: 10.3390/jpm11090847.
    • Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.
    • Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.
    • Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.
    • Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    • Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ.
    • Breast Cancer Res Treat. 2021 Aug 20. doi: 10.1007/s10549-021-06292-7. Epub ahead of print.
    • Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis.
    • Jiang Y, Meng XY, Deng NN, Meng C, Li LH, He ZK, Wang XY, Song ZY, Cui RJ.
    • Front Oncol. 2021 Aug 20;11:718761. doi: 10.3389/fonc.2021.718761.
    • Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
    • Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV.
    • Int J Mol Sci. 2021 Aug 19;22(16):8924. doi: 10.3390/ijms22168924.
    • Heart Rate Variability-Guided Exercise During Chemotherapy in Triathlete with Stage 1 BRCA1-Mutated Breast Cancer.
    • Talbot A, McCabe M, Daly B, Gallagher D.
    • Ir Med J. 2021 Aug 19;114(7):420.
    • Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
    • Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brüning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL; NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Dörk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, García-Sáenz JA, Giles GG, Grip M, Guénel P, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubinski J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, García-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK.
    • Breast Cancer Res. 2021 Aug 18;23(1):86. doi: 10.1186/s13058-021-01450-7.
    • High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    • Zhu L, Pan JN, Qian Z, Ye WW, Wang XJ, Cao WM.
    • Breast Cancer. 2021 Aug 17. doi: 10.1007/s12282-021-01286-1. Epub ahead of print.
    • Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
    • Franchet C, Hoffmann JS, Dalenc F.
    • Cancers (Basel). 2021 Aug 17;13(16):4132. doi: 10.3390/cancers13164132.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • Guideline: ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 6.

    Press release: ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer. (American Society of Clinical Oncology)

    Guidelines: Management of Hereditary Breast Cancer: Rapid Recommendation Update. (American Society of Clinical Oncology)

    • PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
    • Bosnjak M, Jesenko T, Markelc B, Janzic L, Cemazar M, Sersa G.
    • Bioelectrochemistry. 2021 Aug;140:107832. doi: 10.1016/j.bioelechem.2021.107832. Epub 2021 May 1. Erratum in: Bioelectrochemistry. 2021 Oct;141:107865.
    • Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
    • Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2021 Aug;23(8):1416-1423. doi: 10.1038/s41436-021-01151-8. Epub 2021 May 11.
    • Guidelines
    • Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
    • Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L.
    • Gynecol Oncol. 2021 Aug;162(2):496-505. doi: 10.1016/j.ygyno.2021.05.012. Epub 2021 May 19.
    • Meta-Analysis
    • MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells.
    • Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.
    • Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.
    • Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    • Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA.
    • J Clin Oncol. 2021 Jul 29:JCO2101374. doi: 10.1200/JCO.21.01374. Epub ahead of print.
    • Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    • Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS.
    • J Clin Oncol. 2021 Jul 29:JCO2101392. doi: 10.1200/JCO.21.01392. Epub ahead of print.
    • Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies.
    • Kanwal B.
    • Cureus. 2021 Jul 26;13(7):e16636. doi: 10.7759/cureus.16636.
    • Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
    • Hobbs EA, Litton JK, Yap TA.
    • Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Epub ahead of print.
    • Review
    • A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    • Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM.
    • Oncol Ther. 2021 Jul 25. doi: 10.1007/s40487-021-00162-4. Epub ahead of print.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
    • Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U.
    • Int J Mol Sci. 2021 Jul 23;22(15):7884. doi: 10.3390/ijms22157884.
    • Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study.
    • Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt ANJ, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA.
    • Clin Cancer Res. 2021 Jul 22:clincanres.0310.2021. doi: 10.1158/1078-0432.CCR-21-0310.
    • Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    • Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM.
    • Sci Rep. 2021 Jul 20;11(1):14747. doi: 10.1038/s41598-021-94195-4.
    • Investigational Drug Treatments for Triple-Negative Breast Cancer.
    • Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D.
    • J Pers Med. 2021 Jul 10;11(7):652. doi: 10.3390/jpm11070652.
    • Suppression of DNA Polymerase ß Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
    • Yuhas SC, Mishra A, DeWeese TL, Greenberg MM.
    • ACS Chem Biol. 2021 Jul 9. doi: 10.1021/acschembio.1c00385. Epub ahead of print.
    • Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
    • Raimundo L, Calheiros J, Saraiva L.
    • Cancers (Basel). 2021 Jul 9;13(14):3438. doi: 10.3390/cancers13143438.
    • Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.
    • Caiado J, Castells MC.
    • Curr Allergy Asthma Rep. 2021 Jul 7;21(6):37. doi: 10.1007/s11882-021-01014-x.
    • Review
    • Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers.
    • Licite B, Irmejs A, Maksimenko J, Loža P, Trofimovics G, Miklaševics E, Nazarovs J, Romanovska M, Deicmane J, Irmejs R, Purkalne G, Gardovskis J.
    • Hered Cancer Clin Pract. 2021 Jul 7;19(1):30. doi: 10.1186/s13053-021-00187-w.
    • Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
    • McCrea C, Hettle R, Gulati P, Taneja A, Rajora P.
    • J Comp Eff Res. 2021 Jul 7. doi: 10.2217/cer-2021-0097. Epub ahead of print.
    • Review
    • Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
    • Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V.
    • Eur J Cancer. 2021 Jul 6;154:35-45. doi: 10.1016/j.ejca.2021.05.037. Epub ahead of print.
    • Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    • Malka MM, Eberle J, Niedermayer K, Zlotos DP, Wiesmüller L.
    • Biomolecules. 2021 Jul 3;11(7):981. doi: 10.3390/biom11070981.
    • Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    • Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M.
    • Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • Precision medicine in breast cancer: From clinical trials to clinical practice.
    • Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G.
    • Cancer Treat Rev. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12.
    • Review
    • BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    • Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.
    • Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
    • Review
    • Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer.
    • [No author given]
    • Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S3-S4. doi: 10.1002/onco.13863. Epub 2021 Jun 21.
    • Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
    • Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D.
    • Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776.
    • An Application of the Patient Rule-Induction Method to Detect Clinically Meaningful Subgroups from Failed Phase III Clinical Trials.
    • Dyson G.
    • Int J Clin Biostat Biom. 2021;7(1):038. doi: 10.23937/2469-5831/1510038. Epub 2021 Jun 28.
    • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    • Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators.
    • N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.

    News: 'Exciting': Olaparib Benefit Also in Early BRCA+ Breast Cancer. (Medscape)

    Press: Drug may help more women survive hereditary breast cancer. (The Guardian)

    Press: Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study Finds. (The Wall Street Journal)

    Letter, Comment:

    Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.

    Letter, Comment:

    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.

    Letter, Comment:

    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.

    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
    • Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S.
    • Diagnostics (Basel). 2021 Jun 23;11(7):E1144. doi: 10.3390/diagnostics11071144.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data.
    • Worcester S.
    • Medscape Oncology. 2021 Jun 21.

    Press Release: ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer. (ASCO)

    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer .
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Jun 17.
    • Relevance of Platinum-Free Interval and BRCA Reversion Mutations for Veliparib Monotherapy After Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    • Puhalla SL, Diéras V, Arun BK, Kaufman B, Wildiers H, Han HS, Ayoub JP, Stearns V, Yuan Y, Helsten T, Riley-Gillis B, Murphy E, Kundu MG, Wu M, Maag D, Ratajczak CK, Ramathal CY, Friedlander M.
    • Clin Cancer Res. 2021 Jun 15:clincanres.0748.2021. doi: 10.1158/1078-0432.CCR-21-0748. Epub ahead of print.
    • Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.
    • Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A.
    • Clin Cancer Res. 2021 Jun 15;27(12):3404-3413. doi: 10.1158/1078-0432.CCR-20-3444. Epub 2021 Jan 27.

    Commentary:

    Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.

    • Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer.
    • Miller KD.
    • Medscape Oncology. 2021 Jun 11.
    • A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1.
    • Aitmagambetova M, Smagulova G, Bekmukhambetov Y, Zavalyonnaya O, Tulyaeva A.
    • Rep Pract Oncol Radiother. 2021 Jun 9;26(3):463-469. doi: 10.5603/RPOR.a2021.0069.
    • Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA.
    • Ann Oncol. 2021 Jun 8:S0923-7534(21)02047-0. doi: 10.1016/j.annonc.2021.06.002. Epub ahead of print.
    • Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion.
    • Hopkins C.
    • GenomeWeb. Disease Areas. Cancer. 2021 Jun 7.
    • News
    • Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    • Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators.
    • Eur J Cancer. 2021 Jun 1;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub ahead of print.
    • PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
    • Yan F, Jiang Q, He M, Shen P.
    • Future Oncol. 2021 Jun;17(18):2381-2393. doi: 10.2217/fon-2020-1175. Epub 2021 Mar 31.
    • Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2021 Jun;161(3):653-659. doi: 10.1016/j.ygyno.2021.03.011. Epub 2021 Mar 15.
    • Landmark trials in the medical oncology management of metastatic breast cancer.
    • Lu P, Santa-Maria CA, Ballinger TJ, Sheng JY.
    • Semin Oncol. 2021 Jun;48(3):246-258. doi: 10.1053/j.seminoncol.2021.06.003. Epub 2021 Jul 16.
    • Review
    • Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings.
    • Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G.
    • Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242.
    • Breast Cancer Predisposition Genes and Synthetic Lethality.
    • Neiger HE, Siegler EL, Shi Y.
    • Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Homologous recombination deficiency: cancer predispositions and treatment implications.
    • Toh MR, Ngeow J.
    • Oncologist. 2021 May 22. doi: 10.1002/onco.13829. Epub ahead of print.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice.
    • Stucci LS, Internò V, Tucci M, Perrone M, Mannavola F, Palmirotta R, Porta C.
    • Genes (Basel). 2021 May 13;12(5):727. doi: 10.3390/genes12050727.
    • Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    • Nagayama A, Vidula N, Bardia A.
    • Oncology (Williston Park). 2021 May 13;35(5):249-254. doi: 10.46883/ONC.2021.3505.0249.
    • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    • Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H.
    • Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
    • Li C, Li X.
    • Onco Targets Ther. 2021 May 3;14:2929-2939. doi: 10.2147/OTT.S298720.
    • Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    • Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
    • Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
    • Cortesi L, Rugo HS, Jackisch C.
    • Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4. Epub 2021 Mar 12.
    • CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects.
    • Apostolou P, Dellatola V, Papadimitriou C, Kalfakakou D, Fountzilas E, Faliakou E, Fountzilas G, Romanidou O, Konstantopoulou I, Fostira F.
    • Cancers (Basel). 2021 Apr 27;13(9):2106. doi: 10.3390/cancers13092106.
    • Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
    • Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A.
    • Cancers (Basel). 2021 Apr 27;13(9):2117. doi: 10.3390/cancers13092117.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.
    • Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H.
    • J Clin Pharmacol. 2021 Apr 24. doi: 10.1002/jcph.1875. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    • Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.
    • Cochrane Database Syst Rev. 2021 Apr 22;4:CD011395. doi: 10.1002/14651858.CD011395.pub2.
    • Review
    • A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
    • Wu R, Adachi K, Koyama Y, Orimoto K, Okazaki M, Asaoka M, Teraoka S, Ueda A, Miyahara K, Kawate T, Kaise H, Yamada K, Sato E, Ishikawa T.
    • J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • Research advances and new challenges in overcoming triple-negative breast cancer.
    • Zong Y, Pegram M.
    • Cancer Drug Resist. 2021;4(3):517-542. doi: 10.20517/cdr.2021.04. Epub 2021 Apr 8.
    • Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    • Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, Jiang Y, Shao Z, Wang Z.
    • J Exp Clin Cancer Res. 2021 Apr 8;40(1):122. doi: 10.1186/s13046-021-01930-w.
    • An overview on breast cancer genetics and recent innovations: Literature survey.
    • Ramya Sree PR, Thoppil JE.
    • Breast Dis. 2021 Apr 7. doi: 10.3233/BD-201040. Epub ahead of print.
    • Review
    • Prädiktive Mutationsdiagnostik bei Mammakarzinomen [Relevant mutations in predictive breast cancer pathology].
    • Kreipe HH, Sinn P.
    • Pathologe. 2021 Apr 6. German. doi: 10.1007/s00292-021-00929-6. Epub ahead of print.
    • Review, [Article in German]
    • Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
    • Schwartzberg LS, Kiedrowski LA.
    • Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962.
    • HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier.
    • Uchida N, Takeshita M, Suda T, Matsui Y, Yoshida M.
    • Int Cancer Conf J. 2021 Apr 3;10(3):181-185. doi: 10.1007/s13691-021-00481-3.
    • Case report
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years.
    • Chaudhary LN.
    • JCO Oncol Pract. 2021 Apr 1:OP2100111. doi: 10.1200/OP.21.00111. Epub ahead of print.
    • Breast cancer.
    • Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G.
    • Lancet. 2021 Apr 1:S0140-6736(20)32381-3. doi: 10.1016/S0140-6736(20)32381-3. Epub ahead of print.
    • Review
    • Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.
    • Grill S, Klein E.
    • Breast Care (Basel). 2021 Apr;16(2):101-107. doi: 10.1159/000513800. Epub 2021 Jan 20.
    • Review
    • A male with primary accessory breast carcinoma in an axilla is strongly suspected of having hereditary breast cancer.
    • Takahashi E, Terata K, Nanjo H, Ishiyama K, Hiroshima Y, Yamaguchi A, Yatsuyanagi M, Kudo C, Wakita A, Takashima S, Sato Y, Imai K, Motoyama S, Minamiya Y.
    • Int Cancer Conf J. 2021 Jan 10;10(2):107-111. doi: 10.1007/s13691-020-00466-8. eCollection 2021 Apr.
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
    • Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A.
    • Cancers (Basel). 2021 Mar 30;13(7):1586. doi: 10.3390/cancers13071586.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
    • Cortesi L, Piombino C, Toss A.
    • J Pers Med. 2021 Mar 28;11(4):245. doi: 10.3390/jpm11040245.

    Original research:

    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

    Original research:

    Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.

    • Delineation of an unknown significance FANCA genetic variant in a recurrent breast cancer patient.
    • Kastora S, Triantafyllidou O, Kounidas G, Vlahos N.
    • BMJ Case Rep. 2021 Mar 24;14(3):e241251. doi: 10.1136/bcr-2020-241251.
    • Case report
    • Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
    • Schick J, Ritchie RP, Restini C.
    • Breast Cancer (Auckl). 2021 Mar 24;15:1178223421995854. doi: 10.1177/1178223421995854.
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • Overview of recent advances in metastatic triple negative breast cancer.
    • O'Reilly D, Sendi MA, Kelly CM.
    • World J Clin Oncol. 2021 Mar 24;12(3):164-182. doi: 10.5306/wjco.v12.i3.164.
    • Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    • Cipriano É, Mesquita A.
    • Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. doi: 10.1177/11782234211002491.
    • Role of Platinums in Triple-Negative Breast Cancer.
    • Lynce F, Nunes R.
    • Curr Oncol Rep. 2021 Mar 22;23(5):50. doi: 10.1007/s11912-021-01041-x.
    • Review
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
    • Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, He S.
    • Aging (Albany NY). 2021 Mar 11;13(6):8975-8988. doi: 10.18632/aging.202724. Epub 2021 Mar 11.
    • Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
    • Chen X, Gao Y, Zhang G, Li B, Ma T, Ma Y, Wang X.
    • J Cancer. 2021 Mar 5;12(9):2643-2653. doi: 10.7150/jca.53303.
    • Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives.
    • Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S, Suto A.
    • Cancers (Basel). 2021 Mar 3;13(5):1078. doi: 10.3390/cancers13051078.
    • Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
    • Oh SY, Rahman S, Sparano JA.
    • Expert Opin Pharmacother. 2021 Mar 1. doi: 10.1080/14656566.2021.1876662. Epub ahead of print.
    • Review
    • [The Treatment of Olaparib for BRCA Positive-Metastatic Breast Cancer Patient].
    • Yamamoto D, Yamamoto C, Okugawa H, Tsubota Y, Kawakami K.
    • Gan To Kagaku Ryoho. 2021 Mar;48(3):455-456. Japanese.
    • Case report, [Article in Japanese]
    • Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation.
    • Ladan MM, van Gent DC, Jager A.
    • Cancers (Basel). 2021 Feb 28;13(5):1004. doi: 10.3390/cancers13051004.
    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.
    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.
    • Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse.
    • Sorrells S, McKinnon KE, McBratney A, Sumey C.
    • NPJ Genom Med. 2021 Feb 22;6(1):17. doi: 10.1038/s41525-021-00181-0.
    • Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production.
    • Zhou S, Liu Y, Jin L, Guo P, Liu Q, Shan J, Luo X, He H, Ma W, Zhang T.
    • J Steroid Biochem Mol Biol. 2021 Feb 19:105853. doi: 10.1016/j.jsbmb.2021.105853. Epub ahead of print.
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Sacituzumab Govitecan in Patients With Metastatic TNBC.
    • Vahdat L.
    • Medscape. Oncology Decision Point. 2021 Feb 3.
    • Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    • Hinchcliff E, Chelariu-Raicu A, Westin SN.
    • Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678.
    • Review
    • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    • Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Duc AN, Chui SY, Husain A, Winer EP, Adams S, Schmid P.
    • J Natl Cancer Inst. 2021 Feb 1:djab004. doi: 10.1093/jnci/djab004. Epub ahead of print.
    • Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
    • Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
    • Clin Breast Cancer. 2021 Feb;21(1):47-56. doi: 10.1016/j.clbc.2020.07.003. Epub 2020 Jul 9.
    • Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    • Di Leone A, Fragomeni SM, Scardina L, Ionta L, Mulè A, Magno S, Terribile D, Masetti R, Franceschini G.
    • Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1910-1915. doi: 10.26355/eurrev_202102_25087.
    • Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review.
    • Lam TC.
    • J Immunother Precis Oncol. 2021 Jan 29 [eCollection 2021 Feb];4(1):16-20. doi: 10.36401/JIPO-20-24.
    • Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    • Chen Z, Wang X, Li X, Zhou Y, Chen K.
    • J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.
    • Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
    • Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, Kim SS.
    • Int J Biol Sci. 2021 Jan 31;17(3):689-701. doi: 10.7150/ijbs.53667.
    • Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
    • Janysek DC, Kim J, Duijf PHG, Dray E.
    • Transl Oncol. 2021 Jan 27;14(3):101012. doi: 10.1016/j.tranon.2021.101012. Epub ahead of print.
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • Possible Beneficial Effects of N-Acetylcysteine for Treatment of Triple-Negative Breast Cancer.
    • Kwon Y.
    • Antioxidants (Basel). 2021 Jan 24;10(2):169. doi: 10.3390/antiox10020169.
    • ASCO 2020: highlights in breast cancer.
    • Bartsch R.
    • Memo. 2021 Jan 24:1-4. doi: 10.1007/s12254-021-00674-9. Epub ahead of print.
    • PDGFRß is an essential therapeutic target for BRCA1-deficient mammary tumors.
    • Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH.
    • Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x.
    • Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
    • Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, Coussy F, Sablin MP, Debled M, Lefeuvre-Plesse C, Goncalves A, Reynier MM, Jacot W, You B, Barthelemy P, Verret B, Isambert N, Tchiknavorian X, Levy C, Thery JC, L'Haridon T, Ferrero JM, Mege A, Del Piano F, Rouleau E, Tran-Dien A, Adam J, Lusque A, Jimenez M, Jacquet A, Garberis I, Andre F.
    • Nat Med. 2021 Jan 18. doi: 10.1038/s41591-020-01189-2. Epub ahead of print.
    • Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection.
    • Brown JM, Wasson MD, Marcato P.
    • Cancers (Basel). 2021 Jan 15;13(2):296. doi: 10.3390/cancers13020296.
    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.
    • Biskupiak J, Unni S, Telford C, Yoo M, Ye X, Deka R, Brixner D, Stenehjem D.
    • BMC Health Serv Res. 2021 Jan 13;21(1):58. doi: 10.1186/s12913-020-06038-z.
    • American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer.
    • Yip CH, Newman LA.
    • JAMA Surg. 2021 Jan 13. doi: 10.1001/jamasurg.2020.6254. Epub ahead of print.
    • Guideline
    • Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2021 Jan 11;10:574813. doi: 10.3389/fonc.2020.574813.
    • Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
    • Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J.
    • Sci Rep. 2021 Jan 8;11(1):82. doi: 10.1038/s41598-020-80081-y.
    • Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    • Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA.
    • Eur J Cancer. 2021 Jan 7;145:44-52. doi: 10.1016/j.ejca.2020.12.007. Epub ahead of print.
    • Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    • Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.
    • PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025.
    • Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness.
    • Zhao Y, Weroha SJ, Goode EL, Liu H, Wang C.
    • BMC Med Inform Decis Mak. 2021 Jan 6;21(1):3. doi: 10.1186/s12911-020-01364-y.
    • PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    • Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M.
    • Bull Cancer. 2021 Jan 6:S0007-4551(20)30504-X. French. doi: 10.1016/j.bulcan.2020.11.007. Epub ahead of print.
    • Review. [Article in French]
    • Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
    • Yamashita M, Kamei Y, Murakami A, Ozaki E, Okujima K, Takemoto K, Takaoka M, Tsukamoto D, Kusakabe E, Shidahara T, Noda H, Aoki R, Taguchi K, Nishiyama K, Eguchi M, Takada Y.
    • Hered Cancer Clin Pract. 2021 Jan 6;19(1):3. doi: 10.1186/s13053-020-00162-x.
    • Case report
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    • Pop L, Suciu I, Ionescu O, Bacalbasa N, Ionescu P.
    • J Med Life. 2021 Jan-Mar;14(1):17-20. doi: 10.25122/jml-2020-0132.
    • Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
    • Brown LC, Salgado R, Luen SJ, Savas P, Loi S.
    • Cancer J. 2021 Jan-Feb 01;27(1):25-31. doi: 10.1097/PPO.0000000000000501.
    • Review
    • PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    • Layman RM, Arun B.
    • Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
    • Review
    • Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy.
    • Chang X, Sun D, Shi D, Wang G, Chen Y, Zhang K, Tan H, Liu J, Liu B, Ouyang L.
    • Acta Pharm Sin B. 2021 Jan;11(1):156-180. doi: 10.1016/j.apsb.2020.06.003. Epub 2020 Jun 24.
    • Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast.
    • Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21.
    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2021 Jan;32(1):58-65. doi: 10.1016/j.annonc.2020.10.475. Epub 2020 Oct 21.
    • BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
    • Trusler O, Goodwin J, Laslett AL.
    • Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188459. doi: 10.1016/j.bbcan.2020.188459. Epub 2020 Oct 29.
    • Review
    • Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
    • Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M.
    • Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31.
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    • Tsunoda Y, Sasaki A, Sakamoto N, Haruyama Y, Nashimoto M, Koshida Y, Fukuma E.
    • Gan To Kagaku Ryoho. 2021 Jan;48(1):53-56.
    • [Article in Japanese]
    • Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    • Allison KH.
    • Mod Pathol. 2021 Jan;34(Suppl 1):94-106. doi: 10.1038/s41379-020-00704-7. Epub 2020 Nov 5.
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    • Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
    • Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14.

    Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)

    • Integrating PARP inhibitors into the management of breast cancer: where are we?
    • Azim HA, Kassem L, Azim H Jr.
    • Chin Clin Oncol. 2020 Dec 31:cco-19-230. doi: 10.21037/cco-19-230. Epub ahead of print.
    • Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    • Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A.
    • ESMO Open. 2020 Dec 31;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub ahead of print.
    • Immunosuppressive Macrophages Limit PARP Inhibitor Efficacy in TNBC.
    • [No author given]
    • Cancer Discov. 2020 Dec 30:CD-RW2020-185. doi: 10.1158/2159-8290.CD-RW2020-185. Epub ahead of print.
    • Research news
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Surgical Treatment after Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study.
    • Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, Peppercorn J, Borges VF, Warner E, Vardeh H, Collins LC, Gaither R, King TA, Partridge AH.
    • Ann Surg. 2020 Dec 23;Publish Ahead of Print. doi: 10.1097/SLA.0000000000004296. Epub ahead of print.
    • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    • Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE.
    • J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.

    Commentary, Review:

    Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

    • DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.
    • Mirza-Aghazadeh-Attari M, Recio MJ, Darband SG, Kaviani M, Safa A, Mihanfar A, Sadighparvar S, Karimian A, Alemi F, Majidinia M, Yousefi B.
    • DNA Repair (Amst). 2020 Dec 17;98:103032. doi: 10.1016/j.dnarep.2020.103032. Epub ahead of print.
    • Review
    • Germline TP53 Testing in Breast Cancers: Why, When and How?
    • Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T.
    • Cancers (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762.
    • Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status.
    • Hopkins C.
    • Precision Oncology News. 2020 Dec 11.
    • Conference news
    • In Patients With Metastatic TNBC and a Deleterious BRCA Mutation, How Do You Decide Between a PARPi and an Immunotherapy-Based Combination as Initial Therapy?
    • Domchek S.
    • Medscape. Oncology Decision Point. 2020 Dec 9.
    • Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS.
    • Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681.
    • Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.
    • Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB.
    • Biochem Pharmacol. 2020 Dec 4:114359. doi: 10.1016/j.bcp.2020.114359. Epub ahead of print.
    • Editorial: Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment.
    • Grabenstetter A, Lazaro C, Turashvili G.
    • Front Oncol. 2020 Dec 2;10:618369. doi: 10.3389/fonc.2020.618369.
    • Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
    • Cheng HW, Chiang CS, Ho HY, Chou SH, Lai YH, Shyu WC, Chen SY.
    • J Control Release. 2020 Dec 2:S0168-3659(20)30718-5. doi: 10.1016/j.jconrel.2020.11.061. Epub ahead of print.
    • Biomarkers in Her2- Positive Disease.
    • Klocker EV, Suppan C.
    • Breast Care (Basel). 2020 Dec;15(6):586-593. doi: 10.1159/000512283. Epub 2020 Oct 28.
    • Novel therapies for triple-negative breast cancer.
    • Nanda R.
    • Clin Adv Hematol Oncol. 2020 Dec;18(12):799-801.
    • [A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine].
    • Sato T, Kouno T, Hirose S, Oikawa H, Machino C, Funakoshi S.
    • Gan To Kagaku Ryoho. 2020 Dec;47(13):1747-1749.
    • Case report. [Article in Japanese]
    • Triple-negative breast cancer therapy: Current and future perspectives (Review).
    • Won KA, Spruck C.
    • Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.
    • Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    • Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z.
    • J Enzyme Inhib Med Chem. 2020 Dec;35(1):1606-1615. doi: 10.1080/14756366.2020.1804382.
    • A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities.
    • Webb MJ, Kukard C.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975861. doi: 10.1177/1534735420975861. [First Published November 27, 2020.]
    • Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.
    • Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X.
    • Aging (Albany NY). 2020 Nov 30;12. doi: 10.18632/aging.202152. Epub ahead of print.
    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.
    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.
    • Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.
    • Singh B, Yang S, Krishna A, Sridhar S.
    • Front Chem. 2020 Nov 23;8:594619. doi: 10.3389/fchem.2020.594619.
    • Triple-negative breast cancer: promising prognostic biomarkers currently in development.
    • Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N.
    • Expert Rev Anticancer Ther. 2020 Nov 16. doi: 10.1080/14737140.2021.1840984. Epub ahead of print.
    • Review
    • Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    • Nagaraj G, Ma CX.
    • Adv Ther. 2020 Nov 15. doi: 10.1007/s12325-020-01552-2. Epub ahead of print.
    • A review of current progress in triple-negative breast cancer therapy.
    • Shen M, Pan H, Chen Y, Xu YH, Yang W, Wu Z.
    • Open Med (Wars). 2020 Nov 14;15(1):1143-1149. doi: 10.1515/med-2020-0138.
    • Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.
    • Palleschi M, Iaia ML, Casadei C.
    • Breast Cancer Res Treat. 2020 Nov 10. doi: 10.1007/s10549-020-06010-9. Epub ahead of print.
    • Letter

    Original research:

    Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

    • Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.
    • Wang CJ, Xu Y, Lin Y, Zhu HJ, Zhou YD, Mao F, Zhang XH, Huang X, Zhong Y, Sun Q, Li CG.
    • Front Oncol. 2020 Nov 9;10:592998. doi: 10.3389/fonc.2020.592998.
    • BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.
    • Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    • Grinda T, Delaloge S.
    • Ann Oncol. 2020 Nov;31(11):1432-1434. doi: 10.1016/j.annonc.2020.09.018. Epub 2020 Sep 29.

    Original research:

    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

    • Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    • Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J.
    • Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20.

    Editorial:

    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?

    Commentary:

    PARP inhibitors coming of age.

    • Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
    • Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.
    • Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
    • BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
    • Sniadecki M, Brzezinski M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, Kmiec N, Wydra D.
    • Genes (Basel). 2020 Oct 24;11(11):1251. doi: 10.3390/genes11111251.
    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • Innovations in targeted therapies for triple negative breast cancer.
    • McCann KE, Hurvitz SA.
    • Curr Opin Obstet Gynecol. 2020 Oct 21. doi: 10.1097/GCO.0000000000000671. Epub ahead of print.
    • Review
    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
    • Pouptsis A, Swafe L, Patwardhan M, Stavraka C.
    • Front Oncol. 2020 Oct 20;10:553080. doi: 10.3389/fonc.2020.553080. PMID: 33194613; PMCID: PMC7607003.
    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review
    • Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
    • Vidula N, Ellisen LW, Bardia A.
    • J Natl Compr Canc Netw. 2020 Oct 15:1-9. doi: 10.6004/jnccn.2020.7600. Epub ahead of print.
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    • Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH.
    • Breast Cancer Res Treat. 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2. Epub 2020 Jul 26.
    • Was ist neu bei der Diagnostik und Therapie des Mammakarzinoms? – Aktuelle Standards in der Behandlung von Brustkrebs [Breast cancer - state of the art - Short overview of the current standard of treatment].
    • Albert A, Stüber T, Bauer J, Wöckel A.
    • Dtsch Med Wochenschr. 2020 Oct;145(20):1460-1463. German. doi: 10.1055/a-1026-3620. Epub 2020 Oct 6.
    • Review, [Article in German]
    • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK.
    • Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27.

    Commentary:

    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

    Commentary:

    PARP inhibitors coming of age.

    • Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    • Preobrazhenskaya EV, Shleykina AU, Gorustovich OA, Martianov AS, Bizin IV, Anisimova EI, Sokolova TN, Chuinyshena SA, Kuligina ES, Togo AV, Belyaev AM, Ivantsov AO, Sokolenko AP, Imyanitov EN.
    • Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33317. Epub ahead of print.
    • Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    • Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    • PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197.
    • Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    • Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT.
    • PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.
    • JNCI Cancer Spectr. 2020 Sep 18;5(1):pkaa083. doi: 10.1093/jncics/pkaa083.
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
    • Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB; kConFab Investigators, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ; HEBON Investigators, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN; SWE-BRCA Investigators, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H.
    • NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6.
    • Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
    • Corso G, Magnoni F.
    • Eur J Cancer Prev. 2020 Sep 3. doi: 10.1097/CEJ.0000000000000624. Epub ahead of print.
    • Review
    • The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    • Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE.
    • Expert Opin Investig Drugs. 2020 Sep 1. doi: 10.1080/13543784.2020.1818067. Epub ahead of print.
    • Review
    • Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    • Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
    • Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.
    • Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.
    • Huang X, Liu JQ, Zhou YD, Xu Y, Chen C, Wang X, Cao X, Yao R, Sun Q.
    • Ann Transl Med. 2020 Sep;8(18):1183. doi: 10.21037/atm-20-5996.
    • [Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
    • Suzuki H, Oshino T, Hagio K, Takeshita T, Yamashita H.
    • Gan To Kagaku Ryoho. 2020 Sep;47(9):1351-1353. Japanese.
    • Case report. [Article in Japanese]
    • Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    • Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B.
    • Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.

    Comment, Letter:

    Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.

    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    • Goncalves A, Mezni E, Bertucci F.
    • Curr Opin Oncol. 2020 Aug 26. doi: 10.1097/CCO.0000000000000680. Epub ahead of print.
    • Review
    • Management of early breast cancer in patients bearing germline BRCA mutations.
    • t'Kint de Roodenbeke MD, Pondé N, Buisseret L, Piccart M.
    • Semin Oncol. 2020 Aug 18:S0093-7754(20)30083-X. doi: 10.1053/j.seminoncol.2020.07.006. Epub ahead of print.
    • Review
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    • Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP.
    • Ann Oncol. 2020 Aug 13:S0923-7534(20)42061-7. doi: 10.1016/j.annonc.2020.08.2064. Epub ahead of print.
    • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    • Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.
    • JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.2965. Epub ahead of print.
    • Basket Trial Data Supports Further Study of Lynparza, Imfinzi Regimen in BRCA-Mutated Breast Cancer.
    • Ray T.
    • Precision Oncology News. 2020 Aug 12.
    • Research news
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease.
    • Cen C, Chun J, Schnabel F.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13964. Online ahead of print.
    • Review
    • Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    • Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.
    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.
    • Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
    • Peleg Hasson S, Menes T, Sonnenblick A.
    • Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • Current and Emerging Biologic Therapies for Triple Negative Breast Cancer.
    • Shaikh SS, Emens LA.
    • Expert Opin Biol Ther. 2020 Jul 25. doi: 10.1080/14712598.2020.1801627. Epub ahead of print.
    • Review
    • Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts.
    • Di Raimo T, Angelini F.
    • J Clin Med. 2020 Jul 25;9(8):E2377. doi: 10.3390/jcm9082377.
    • Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
    • Kuemmel S, Harrach H, Schmutzler RK, Kostara A, Ziegler-Löhr K, Dyson MH, Chiari O, Reinisch M.
    • NPJ Breast Cancer. 2020 Jul 24;6:31. doi: 10.1038/s41523-020-00174-9.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    • Go A, Jang JW, Lee W, Ha JD, Kim HJ, Nam HJ.
    • Eur J Med Chem. 2020 Jul 19;204:112635. doi: 10.1016/j.ejmech.2020.112635. Epub ahead of print.
    • Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
    • González-Martínez S, Pérez-Mies B, Carretero-Barrio I, Palacios-Berraquero ML, Perez-García J, Cortés J, Palacios J.
    • Cancers (Basel). 2020 Jul 8;12(7):E1832. doi: 10.3390/cancers12071832.
    • Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
    • Desai NV, Tung NM.
    • Breast J. 2020 Jul 6. doi: 10.1111/tbj.13972. Epub ahead of print.
    • Review
    • Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.
    • Printz C.
    • Cancer. 2020 Jul 1;126(13):2955. doi: 10.1002/cncr.32999.

    Original research:

    Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.

    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    • Du F, Wang W, Wang Y, Li M, Zhu A, Wang J, Cai R, Ma F, Fan Y, Li Q, Zhang P, Todorovic V, Yuan P, Xu B.
    • Breast Cancer Res Treat. 2020 Jul;182(1):67-77. doi: 10.1007/s10549-020-05648-9. Epub 2020 May 11.
    • [A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
    • Yabe S, Iwamoto N, Inokuchi T, Nara M, Saita C, Onishi M, Goto R, Yonekura R, Ishiba T, Honda Y, Miyamoto H, Aruga T.
    • Gan To Kagaku Ryoho. 2020 Jul;47(7):1089-1092. Japanese.
    • Case report. [Article in Japanese.]
    • The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    • Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.
    • Hum Reprod. 2020 Jun 30:deaa128. doi: 10.1093/humrep/deaa128. Epub ahead of print.
    • Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
    • Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, Laurentiis M.
    • Int J Mol Sci. 2020 Jun 27;21(13):E4579. doi: 10.3390/ijms21134579.
    • NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
    • Miao K, Lei JH, Valecha MV, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, Su SM, Shao F, Rajendran BK, Bao J, Zeng J, Sun H, Chen P, Tan K, Chen Q, Wong KH, Xu X, Deng CX.
    • Nat Commun. 2020 Jun 26;11(1):3256. doi: 10.1038/s41467-020-16936-9.
    • Metastatic triple-negative breast cancer: Established and emerging treatments.
    • Puri A, Reddy TP, Patel TA, Chang JC.
    • Breast J. 2020 Jun 23. doi: 10.1111/tbj.13946. Epub ahead of print.
    • Review
    • Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    • Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.
    • Clin Cancer Res. 2020 Jun 22:clincanres.0638.2020. doi: 10.1158/1078-0432.CCR-20-0638. Epub ahead of print.
    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • Study: Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in a gene that repairs DNA damage.
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 18.

    Conference abstract:

    TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

    • Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.
    • Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS.
    • Cancer Discov. 2020 Jun 12:CD-20-0163. doi: 10.1158/2159-8290.CD-20-0163. Epub ahead of print.
    • Triple-negative breast cancer molecular subtyping and treatment progress.
    • Yin L, Duan JJ, Bian XW, Yu SC.
    • Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
    • Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
    • Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B.
    • Breast J. 2020 Jun 4. doi: 10.1111/tbj.13922. Epub ahead of print.
    • Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    • Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
    • BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.
    • Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig? [Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?].
    • Schmidt M.
    • J Gynakol Endokrinol. 2020 Jun 2:1-3. German. doi: 10.1007/s41974-020-00141-z. Epub ahead of print.
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
    • Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J.
    • Chin J Cancer Res. 2020 Jun;32(3):370-382. doi: 10.21147/j.issn.1000-9604.2020.03.08.
    • Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population.
    • Huang X, Cai XY, Liu JQ, Hao WW, Zhou YD, Wang X, Xu Y, Chen C, Lin Y, Wang CJ, Song Y, Sun Q.
    • Gland Surg. 2020 Jun;9(3):775-787. doi: 10.21037/gs-20-531.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
    • Lee JS, Yost SE, Yuan Y.
    • Cancers (Basel). 2020 May 29;12(6):E1404. doi: 10.3390/cancers12061404.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    • Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.
    • Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.
    • Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    • Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1623. Epub ahead of print.
    • Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    • Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1626. Epub ahead of print.
    • The evolving management of metastatic triple negative breast cancer.
    • Malhotra MK, Emens LA.
    • Semin Oncol. 2020 May 28:S0093-7754(20)30044-0. doi: 10.1053/j.seminoncol.2020.05.005.
    • Review
    • PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
    • Gonçalves A, Bertucci A, Bertucci F.
    • Cancers (Basel). 2020 May 27;12(6):E1378. doi: 10.3390/cancers12061378.
    • Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
    • Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.
    • [New advances in targeted therapy for breast cancer].
    • Zhao J, Wu N, Zhang SC, Zhao ZW, Li LJ, Liu JT.
    • Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. Chinese. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
    • Review, [Article in Chinese]
    • High-throughput functional evaluation of BRCA2 variants of unknown significance.
    • Ikegami M, Kohsaka S, Ueno T, Momozawa Y, Inoue S, Tamura K, Shimomura A, Hosoya N, Kobayashi H, Tanaka S, Mano H.
    • Nat Commun. 2020 May 22;11(1):2573. doi: 10.1038/s41467-020-16141-8.
    • AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer.
    • Anderson A.
    • Precision Oncology News. 2020 May 14.
    • Novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor DDHCB inhibits proliferation of BRCA mutant breast cancer cell in vitro and in vivo through a synthetic lethal mechanism.
    • Wang L, Zhang S, Yu X, Guo C.
    • Chem Res Toxicol. 2020 May 12. doi: 10.1021/acs.chemrestox.0c00087. Epub ahead of print.
    • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
    • Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE.
    • J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25.

    Letter, Commentary:

    Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.

    • Integrating Genetic and Genomic Testing Into Oncology Practice.
    • Domchek SM, Mardis E, Carlisle JW, Owonikoko TK.
    • Am Soc Clin Oncol Educ Book. 2020 May;40:e259-e263. doi: 10.1200/EDBK_280607.
    • [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
    • Yoneda H, Shimizu Y, Masuda R.
    • Gan To Kagaku Ryoho. 2020 May;47(5):815-818.
    • Case report, [Article in Japanese]
    • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    • Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
    • Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
    • Review
    • A single nucleotide variant of human PARP1 determines response to PARP inhibitors.
    • Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S.
    • NPJ Precis Oncol. 2020 Apr 27;4:10. doi: 10.1038/s41698-020-0113-2. eCollection 2020.
    • Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    • Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.
    • Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.
    • Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
    • Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN.
    • Fertil Steril. 2020 Apr 21. pii: S0015-0282(20)30036-4. doi: 10.1016/j.fertnstert.2020.01.033. [Epub ahead of print]
    • BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    • Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.
    • Breast Cancer Res Treat. 2020 Apr 20. doi: 10.1007/s10549-020-05647-w. [Epub ahead of print]
    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
    • Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA.
    • Cancers (Basel). 2020 Apr 14;12(4). pii: E972. doi: 10.3390/cancers12040972.
    • Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    • Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK.
    • Med Oncol. 2020 Apr 10;37(5):48. doi: 10.1007/s12032-020-01371-z.
    • Case report
    • Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    • Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S.
    • Int J Gynecol Cancer. 2020 Apr 9. pii: ijgc-2020-001288. doi: 10.1136/ijgc-2020-001288. [Epub ahead of print]
    • Biologic therapy for advanced breast cancer: recent advances and future directions.
    • Tarantino P, Morganti S, Curigliano G.
    • Expert Opin Biol Ther. 2020 Apr 7. doi: 10.1080/14712598.2020.1752176. [Epub ahead of print]
    • Review
    • Olaparib for advanced breast cancer.
    • Griguolo G, Dieci MV, Miglietta F, Guarneri V, Conte P.
    • Future Oncol. 2020 Apr 6. doi: 10.2217/fon-2019-0689. [Epub ahead of print]
    • Review
    • Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
    • Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS.
    • Acta Pharm Sin B. 2020 Apr;10(4):615-627. doi: 10.1016/j.apsb.2019.08.008. Epub 2019 Sep 5.
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13.
    • Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
    • Wang N, Li K, Huang W, Kong W, Liu X, Shi W, Xie F, Jiang H, Song G, Di L, Wang Q, Yu J, Li H.
    • Chin J Cancer Res. 2020 Apr;32(2):149-162. doi: 10.21147/j.issn.1000-9604.2020.02.03.
    • Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
    • Lüftner D, Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lux MP.
    • Geburtshilfe Frauenheilkd. 2020 Apr;80(4):391-398. doi: 10.1055/a-1111-8775. Epub 2020 Apr 21.
    • [Hereditary breast carcinomas pathologist's perspective].
    • Vincent-Salomon A, Bataillon G, Djerroudi L.
    • Ann Pathol. 2020 Mar 30. pii: S0242-6498(20)30059-6. doi: 10.1016/j.annpat.2020.02.023. [Epub ahead of print]
    • Review, [Article in French]
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
    • Testa U, Castelli G, Pelosi E.
    • Med Sci (Basel). 2020 Mar 23;8(1). pii: E18. doi: 10.3390/medsci8010018.
    • Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    • Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A.
    • Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362-6. doi: 10.1016/j.annonc.2020.03.283. [Epub ahead of print]
    • Case report
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
    • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0007. [Epub ahead of print]
    • The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
    • Patel M, Nowsheen S, Maraboyina S, Xia F.
    • Cell Biosci. 2020 Mar 11;10:35. doi: 10.1186/s13578-020-00390-7. eCollection 2020.
    • PARP and PARG inhibitors in cancer treatment.
    • Slade D.
    • Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
    • Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
    • Li A, Schleicher SM, Andre F, Mitri ZI.
    • Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-14. doi: 10.1200/EDBK_280463.
    • BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
    • Lee A, Moon BI, Kim TH.
    • Ann Lab Med. 2020 Mar;40(2):114-121. doi: 10.3343/alm.2020.40.2.114.
    • Review

    Introductory article:

    From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer.

    • OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer.
    • Sanchez AM, Orlandi A, Franceschini G, De Lauretis F, Terribile D, Franco A, Masetti R.
    • Ann Palliat Med. 2020 Mar;9(2):510-511. doi: 10.21037/apm.2020.01.14. Epub 2020 Feb 16.
    • Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    • Criscitiello C, Curigliano G.
    • Eur J Cancer. 2020 Mar;127:236-239. doi: 10.1016/j.ejca.2019.12.004. Epub 2020 Jan 20.
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.
    • Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y.
    • Front Oncol. 2020 Feb 28;10:301. doi: 10.3389/fonc.2020.00301. eCollection 2020.
    • Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
    • García IA, Garro C, Fernandez E, Soria G.
    • Mutat Res. 2020 Feb 25;821:111693. doi: 10.1016/j.mrfmmm.2020.111693. [Epub ahead of print]
    • Review
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    • Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
    • Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119. doi: 10.3390/diagnostics10020119.
    • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    • Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N.
    • Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055-5. doi: 10.1016/j.annonc.2020.02.008. [Epub ahead of print]
    • Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
    • Kaplan HG, Calip GS, Malmgren JA.
    • Oncologist. 2020 Feb 19. doi: 10.1634/theoncologist.2019-0099. [Epub ahead of print]
    • BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    • Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E.
    • Sci Transl Med. 2020 Feb 19;12(531). pii: eaax2625. doi: 10.1126/scitranslmed.aax2625.
    • Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    • Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L.
    • Expert Opin Pharmacother. 2020 Feb 13:1-13. doi: 10.1080/14656566.2020.1724957. [Epub ahead of print]
    • Review
    • BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    • Guo C, Zhang F, Wu X, Yu X, Wu X, Shi D, Wang L.
    • Int J Biol Macromol. 2020 Feb 10. pii: S0141-8130(19)39269-4. doi: 10.1016/j.ijbiomac.2020.02.069. [Epub ahead of print]
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    • Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K, Oba M, Ishikawa T.
    • J Surg Res. 2020 Feb 7;250:143-147. doi: 10.1016/j.jss.2019.12.047. [Epub ahead of print]
    • Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2020 Feb 6:e196400. doi: 10.1001/jamaoncol.2019.6400. [Epub ahead of print]

    Press: Breast Cancer Care After Genetic Testing Often Doesn’t Follow Guidelines. (Clinical OMICs)

    Research news:

    Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.

    • BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.
    • Tazzite A, Jouhadi H, Benider A, Nadifi S.
    • Curr Drug Targets. 2020 Feb 3. doi: 10.2174/1389450121666200203162541. [Epub ahead of print]
    • Review
    • Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    • Xiao Q, Zhou Y, Winter S, Büttner F, Schaeffeler E, Schwab M, Lauschke VM.
    • Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898. [Epub ahead of print]
    • Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
    • Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC.
    • Am J Cancer Res. 2020 Feb 1;10(2):648-661. eCollection 2020.
    • Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis.
    • Ricci AD, Rizzo A, Novelli M, Tavolari S, Palloni A, Tober N, Abbati F, Mollica V, DE Lorenzo S, Turchetti D, DI Marco M, Brandi G.
    • Anticancer Res. 2020 Feb;40(2):597-608. doi: 10.21873/anticanres.13989.
    • Review
    • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
    • Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching PA, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K.
    • Breast Care (Basel). 2020 Feb;15(1):82-95. doi: 10.1159/000505957. Epub 2020 Feb 10.
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • PARP inhibitors: a tsunami of indications in different malignancies.
    • Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.
    • Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.
    • Review
    • BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    • Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.
    • Oncology. 2020 Jan 21:1-4. doi: 10.1159/000504965. [Epub ahead of print]
    • Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    • de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M.
    • Eur J Cancer. 2020 Jan 16. pii: S0959-8049(19)30855-X. doi: 10.1016/j.ejca.2019.12.003. [Epub ahead of print]
    • Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE Jr, Sikov WM, Untch M.
    • JAMA Surg. 2020 Jan 8:e195410. doi: 10.1001/jamasurg.2019.5410. [Epub ahead of print]
    • The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
    • Yusoh NA, Leong SW, Chia SL, Harun SN, Abdul Rahman MB, Vallis KA, Gill MR, Ahmad H.
    • ACS Chem Biol. 2020 Jan 3. doi: 10.1021/acschembio.9b00843. [Epub ahead of print]
    • CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
    • Mintz RL, Lao YH, Chi CW, He S, Li M, Quek CH, Shao D, Chen B, Han J, Wang S, Leong KW.
    • Bioeng Transl Med. 2020 Jan 2;5(1):e10152. doi: 10.1002/btm2.10152. eCollection 2020 Jan.
    • DNA damage repair functions and targeted treatment in breast cancer.
    • He C, Kawaguchi K, Toi M.
    • Breast Cancer. 2020 Jan 2. doi: 10.1007/s12282-019-01038-2. [Epub ahead of print]
    • Review
    • Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    • Cheng AS, Leung SCY, Gao D, Burugu S, Anurag M, Ellis MJ, Nielsen TO.
    • Breast Cancer Res Treat. 2020 Jan;179(1):3-10. doi: 10.1007/s10549-019-05438-y. Epub 2019 Sep 14.

    Letter, Comment:

    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.

    • [Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].
    • Aimono E, Iguchi A, Mochida K, Imai M, Hayashi H, Nishihara H.
    • Yakugaku Zasshi. 2020;140(5):667-668. doi: 10.1248/yakushi.19-00217-4.
    • Conference abstract, [Article in Japanese]
    • [Our Treatment Strategy for Patients with Hereditary Breast Cancer Syndrome in Hamamatsu Medical Center].
    • Miyamoto Y, Tochikubo J, Hosokawa Y, Amano K.
    • Yakugaku Zasshi. 2020;140(5):669-671. doi: 10.1248/yakushi.19-00217-5.
    • BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab.
    • Lin J, Yang X, Zhao H.
    • JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.4595. [Epub ahead of print]
    • Letter, Comment

    Letter, Reply:

    BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply.

    Original research:

    Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

    Original research:

    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

    • Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.
    • Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.
    • J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.
    • Triple negative breast cancer: A thorough review of biomarkers.
    • da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC.
    • Crit Rev Oncol Hematol. 2019 Dec 20;145:102855. doi: 10.1016/j.critrevonc.2019.102855. [Epub ahead of print]
    • Immunotherapy Regimens Yield Contrasting Results in Early Triple Negative Breast Cancer.
    • Ashford M.
    • GenomeWeb. 2019 Dec 12.
    • Research news, Conference report
    • BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
    • Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.
    • JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.
    • BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
    • Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N.
    • Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6.
    • Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    • Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S.
    • Drugs. 2019 Dec 10. doi: 10.1007/s40265-019-01235-5. [Epub ahead of print]
    • Review
    • Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
    • Trenner A, Sartori AA.
    • Front Oncol. 2019 Dec 10;9:1388. doi: 10.3389/fonc.2019.01388. eCollection 2019.
    • Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    • Park HS, Lee JD, Kim JY, Park S, Kim JH, Han HJ, Choi YA, Choi AR, Sohn JH, Kim SI.
    • PLoS One. 2019 Dec 10;14(12):e0225082. doi: 10.1371/journal.pone.0225082. eCollection 2019.
    • Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    • Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.
    • Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]
    • Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    • Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.
    • Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]
    • Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
    • Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D.
    • Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
    • Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer.
    • Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, Park SY, Kim SW, Kim EK.
    • J Breast Cancer. 2019 Sep 30;22(4):587-598. doi: 10.4048/jbc.2019.22.e47. eCollection 2019 Dec.
    • Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    • Exman P, Mallery RM, Lin NU, Parsons HA.
    • NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
    • Hype or hope? The strange case of platinum salts' renaissance in breast cancer.
    • Corvaja C, Garutti M, Gerratana L, Pelizzari G, Puglisi F.
    • Expert Rev Anticancer Ther. 2019 Nov 27. doi: 10.1080/14737140.2019.1699066. [Epub ahead of print]
    • Editorial
    • Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    • Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J.
    • Oncologist. 2019 Nov 25. pii: theoncologist.2019-0493. doi: 10.1634/theoncologist.2019-0493. [Epub ahead of print]
    • Targeted Therapies for Triple-Negative Breast Cancer.
    • Lyons TG.
    • Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.
    • Review
    • Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.
    • Christian N, Zabor EC, Cassidy M, Flynn J, Morrow M, Gemignani ML.
    • Ann Surg Oncol. 2019 Nov 15. doi: 10.1245/s10434-019-08038-8. [Epub ahead of print]
    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer.
    • Saito S, Nakazawa K, Nagahashi M, Ishikawa T, Akazawa K.
    • Per Med. 2019 Nov 6. doi: 10.2217/pme-2018-0141. [Epub ahead of print]
    • The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
    • Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P.
    • NPJ Breast Cancer. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019.
    • Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
    • Fitzpatrick A, Tutt A.
    • Ther Adv Med Oncol. 2019 Nov 1;11:1758835919882581. doi: 10.1177/1758835919882581. eCollection 2019.
    • Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy.
    • Kumeta T, Matsunuma R, Yamaguchi K, Hayami R, Tsuneizumi M.
    • Case Rep Oncol. 2019 Oct 29;12(3):814-819. doi: 10.1159/000503858. eCollection 2019 Sep-Dec.
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
    • Walker-Smith TL, Peck J.
    • Nurs Womens Health. 2019 Oct 25. pii: S1751-4851(19)30188-6. doi: 10.1016/j.nwh.2019.09.003. [Epub ahead of print]
    • Review
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
    • Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W.
    • JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz085. doi: 10.1093/jncics/pkz085. eCollection 2020 Feb.
    • RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    • Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    • Biochim Biophys Acta Mol Basis Dis. 2019 Oct 19:165561. doi: 10.1016/j.bbadis.2019.165561. [Epub ahead of print]
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising.
    • [No author given]
    • FORCE. XRAYS. 2019 Oct 4.

    Original research:

    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

    • Who Should Consider Genetic Counseling and Testing for Breast and Ovarian Cancer? Guidelines Have Expanded.
    • [No author given]
    • My Gene Counsel. 2019 Oct 3.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells.
    • Zhao W, Hu H, Mo Q, Guan Y, Li Y, Du Y, Li L.
    • Int J Clin Exp Pathol. 2019 Oct 1;12(10):3915-3920. eCollection 2019.
    • Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer.
    • Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S.
    • Nutr Cancer. 2019 Oct 1:1-10. doi: 10.1080/01635581.2019.1670216. [Epub ahead of print]
    • Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
    • Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
    • Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
    • Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.
    • Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
    • Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.
    • Nat Med. 2019 Sep 30. doi: 10.1038/s41591-019-0582-4. [Epub ahead of print]
    • PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.
    • Murthy P, Muggia F.
    • Cancer Drug Resist. 2019 Sep 19;2(3):665-679. doi: 10.20517/cdr.2019.002.
    • Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
    • Yu Y, Durairaj C, Shi H, Wang DD.
    • J Clin Pharmacol. 2019 Sep 6. doi: 10.1002/jcph.1520. [Epub ahead of print]
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Sep;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Epub 2019 Dec 12.
    • Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    • Nuthalapati S, Stodtmann S, Shepherd SP, Ratajczak CK, Mensing S, Menon R, Xiong H.
    • Cancer Chemother Pharmacol. 2019 Aug 29. doi: 10.1007/s00280-019-03930-2. [Epub ahead of print]
    • A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    • Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P.
    • Sci Rep. 2019 Aug 29;9(1):12511. doi: 10.1038/s41598-019-48929-0.
    • Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    • Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worm H1, Moulder SL, Arun BK.
    • J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

    Research news: Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising. (FORCE. XRAYS.)

    • A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
    • Xu K, Shi Y, Wang X, Chen Y, Tang L, Guan X.
    • Cancer Genet. 2019 Aug 23;239:26-32. doi: 10.1016/j.cancergen.2019.08.004. [Epub ahead of print]
    • Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    • Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P.
    • Eur J Cancer. 2019 Aug 22;120:20-30. doi: 10.1016/j.ejca.2019.06.023. [Epub ahead of print]
    • EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.
    • Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B.
    • Nanomedicine (Lond). 2019 Aug 21. doi: 10.2217/nnm-2019-0132. [Epub ahead of print]
    • Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
    • Boraei ATA, Singh PK, Sechi M, Satta S.
    • Eur J Med Chem. 2019 Aug 14;182:111621. doi: 10.1016/j.ejmech.2019.111621. [Epub ahead of print]
    • A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
    • Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT.
    • Theranostics. 2019 Aug 14;9(21):6224-6238. doi: 10.7150/thno.36281. eCollection 2019.
    • Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
    • Militello AM, Zielli T, Boggiani D, Michiara M, Naldi N, Bortesi B, Zanelli P, Uliana V, Giuliotti S, Musolino A.
    • Front Oncol. 2019 Aug 13;9:759. doi: 10.3389/fonc.2019.00759. eCollection 2019.
    • Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
    • West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE.
    • Cancer Med. 2019 Aug 12. doi: 10.1002/cam4.2471. [Epub ahead of print]
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Homologous recombination DNA repair defects in PALB2-associated breast cancers.
    • Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.
    • NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine.
    • Kerr DJ.
    • Medscape Oncology. 2019 Jul 18.

    Original research:

    Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
    • Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, Leheurteur M, Demeestere I, Di Fiore F, Perdrix A, Clatot F.
    • Front Oncol. 2019 Jul 12;9:575. doi: 10.3389/fonc.2019.00575. eCollection 2019.
    • Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
    • Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.
    • Int J Mol Sci. 2019 Jul 10;20(14). pii: E3390. doi: 10.3390/ijms20143390.
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
    • Kim H, Lin Q, Yun Z.
    • Sci Rep. 2019 Jul 4;9(1):9702. doi: 10.1038/s41598-019-46210-y.
    • Evidence to date: talazoparib in the treatment of breast cancer.
    • Exman P, Barroso-Sousa R, Tolaney SM.
    • Onco Targets Ther. 2019 Jul 2;12:5177-5187. doi: 10.2147/OTT.S184971. eCollection 2019.
    • Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy.
    • Wang M, Huang J, Chagpar AB.
    • Am Surg. 2019 Jul 1;85(7):768-771.
    • Targeting DNA repair in breast cancer.
    • Paluch-Shimon S, Evron E.
    • Breast. 2019 Jul 1;47:33-42. doi: 10.1016/j.breast.2019.06.007. [Epub ahead of print]
    • Review
    • Talazoparib to treat BRCA-positive breast cancer.
    • Guney Eskiler G.
    • Drugs Today (Barc). 2019 Jul;55(7):459-467. doi: 10.1358/dot.2019.55.7.3015642.
    • Review
    • Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
    • Kundur S, Prayag A, Selvakumar P, Nguyen H, McKee L, Cruz C, Srinivasan A, Shoyele S, Lakshmikuttyamma A.
    • J Cell Physiol. 2019 Jul;234(7):11103-11118. doi: 10.1002/jcp.27761. Epub 2018 Nov 27.
    • Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.
    • Semushina SG, Aronov DA, Moiseeva EV.
    • Pathol Oncol Res. 2019 Jul;25(3):945-951. doi: 10.1007/s12253-018-0396-6. Epub 2018 Mar 6.
    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    • Aktas BY, Guner G, Guven DC, Arslan C, Dizdar O.
    • Expert Rev Anticancer Ther. 2019 Jun 10. doi: 10.1080/14737140.2019.1631162. [Epub ahead of print]
    • Review
    • Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
    • Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 7];3:1-6. doi: 10.1200/PO.19.00012.
    • [Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.]
    • Palácová M.
    • Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.
    • [Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.]
    • Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • Therapeutic innovations in breast cancer.
    • Le Du F, Perrin C, Brunot A, Crouzet L, De La Motte Rouge T, Lefeuvre-Plesse C, Dieras V.
    • Presse Med. 2019 May 29. pii: S0755-4982(19)30165-4. doi: 10.1016/j.lpm.2019.04.005. [Epub ahead of print]
    • Review
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer.
    • Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32424. [Epub ahead of print]
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
    • Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.
    • Rev Med Suisse. 2019 May 15;15(651):1027-1031.
    • Review, [Article in French]
    • A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
    • Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.
    • Cancers (Basel). 2019 May 13;11(5):665. doi: 10.3390/cancers11050665.
    • How I treat metastatic triple-negative breast cancer.
    • Caparica R, Lambertini M, de Azambuja E.
    • ESMO Open. 2019 May 13;4(Suppl 2):e000504. doi: 10.1136/esmoopen-2019-000504. eCollection 2019.
    • A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
    • Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group.
    • Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18.
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review

    Comment, Letter:

    Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers.

    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • [Genetic Approach of Breast Cancer].
    • Takei J, Yamauchi H.
    • Gan To Kagaku Ryoho. 2019 May;46(5):831-837.
    • Review, [Article in Japanese]
    • BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
    • EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.
    • Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips EH, Severson T, van de Ven M, Brambillasca CS, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler RK, Linn SC, Jonkers J.
    • Clin Cancer Res. 2019 Apr 29. pii: clincanres.4024.2018. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.
    • Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.
    • Cancer Discov. 2019 Apr 23. pii: CD-18-1218. doi: 10.1158/2159-8290.CD-18-1218. [Epub ahead of print]
    • Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    • Ma X, Dang C, Min W, Diao Y, Hui W, Wang X, Dai Z, Wang X, Kang H.
    • Breast Cancer Res Treat. 2019 Apr 15. doi: 10.1007/s10549-019-05189-w. [Epub ahead of print]
    • Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
    • Na B, Yu X, Withers T, Gilleran J, Yao M, Foo TK, Chen C, Moore D, Lin Y, Kimball SD, Xia B, Ganesan S, Carpizo DR.
    • NPJ Breast Cancer. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1. eCollection 2019.
    • β-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    • Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.
    • Carcinogenesis. 2019 Apr 9. pii: bgz070. doi: 10.1093/carcin/bgz070. [Epub ahead of print]
    • Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
    • Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ.
    • Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.
    • Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    • Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ.
    • Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
    • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    • Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM.
    • Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.
    • Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    • Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2019 Apr;174(3):627-637. doi: 10.1007/s10549-018-05120-9. Epub 2019 Jan 3.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
    • Force J, Leal JHS, McArthur HL.
    • Curr Treat Options Oncol. 2019 Mar 28;20(4):35. doi: 10.1007/s11864-019-0634-5.
    • Review
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2019 Mar 25;17:11. doi: 10.1186/s13053-019-0111-y. eCollection 2019.
    • DNA polymerase θ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
    • Wang Z, Song Y, Li S, Kurian S, Xiang R, Chiba T, Wu X.
    • J Biol Chem. 2019 Mar 15;294(11):3909-3919. doi: 10.1074/jbc.RA118.005188. Epub 2019 Jan 17.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer.
    • Meijer TG, Verkaik NS, van Deurzen CHM, Dubbink HJ, den Toom TD, Sleddens HFBM, De Hoop EO, Dinjens WNM, Kanaar R, van Gent DC, Jager A.
    • JCO Precis Oncol. 2019 Dec [2019 Mar 11];3:1-12. doi: 10.1200/PO.18.00268.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    • [No author given]
    • N Engl J Med. 2019 Mar 7;380(10):985-988. doi: 10.1056/NEJMc1900150.
    • Letter

    Original research:

    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

    • BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
    • Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, In Chan U, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX.
    • Hum Mol Genet. 2019 Mar 1;28(5):842-857. doi: 10.1093/hmg/ddy398.
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?
    • Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A.
    • Crit Rev Oncol Hematol. 2019 Mar;135:66-75. doi: 10.1016/j.critrevonc.2019.01.016. Epub 2019 Jan 30.
    • Review
    • A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    • Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.
    • Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.
    • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    • Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.
    • Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.
    • Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
    • Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J.
    • Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
    • Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
    • Caulfield SE, Davis CC, Byers KF.
    • J Adv Pract Oncol. 2019 Mar;10(2):167-174. Epub 2019 Mar 1.
    • Review
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • A new paradox for pCR in BRCA mutation carriers.
    • Rounis K, Mavroudis D.
    • Transl Cancer Res. 2019 Mar;8(Suppl 2):S99-S102. doi: 10.21037/tcr.2018.10.25.

    Original research:

    BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

    • AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    • Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C.
    • Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613. doi: 10.1073/pnas.1815126116. Epub 2019 Feb 7.
    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    • Velázquez C, Esteban-Cardeñosa EM, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Durán M, Infante M.
    • Breast. 2019 Feb;43:91-96. doi: 10.1016/j.breast.2018.11.010. Epub 2018 Nov 29.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Treating metastatic breast cancer: Analysis of the impact of palbociclib (Ibrance) on overall survival in the PALOMA-3 trial.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 23.
    • Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    • Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J.
    • Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2.
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    • Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    • Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Improving outcomes for young women with breast cancer: fertility and childbearing issues.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 7.

    ClinicalTrials.gov: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) (NIH. ClinicalTrials.gov.)

    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    • Yap TA, Plummer R, Azad NS, Helleday T.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):185-195. doi: 10.1200/EDBK_238473.
    • Molecular Testing in Breast Cancer.
    • Litton JK, Burstein HJ, Turner NC.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):e1-e7. doi: 10.1200/EDBK_237715.
    • A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    • Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y.
    • Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    • Fremd C, Jaeger D, Schneeweiss A.
    • Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
    • Review
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    • Li N, Wang Y, Deng W, Lin SH.
    • Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.
    • Review

Continue to Older References